AWARD NUMBER: W81XWH-16-1-0230 - Indiana University (Log #PR150219)

**TITLE:** Control of Lung Inflammation by Microbiome and Peptidoglycan Recognition Protein

PRINCIPAL INVESTIGATOR: Roman Dziarski

CONTRACTING ORGANIZATION: Indiana University Bloomington, IN 47401

**REPORT DATE:** July 2018

TYPE OF REPORT: Annual Report

**PREPARED FOR:** U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

**DISTRIBUTION STATEMENT:** Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

CREPORT DOCUMENT AT TON PAGE         OMB IN: CONT 0.004-0183           The applicity laws of any applicity of the any any applicity of the any applicity of the applicity	Б					Form Approved
Part Note: Control of Long Information and the control of the con	R	EPURIDU		NPAGE		OMB No. 0704-0188
Balance Rependent of Edence Neukorgen Hostigates bevoes, Encode all rependent of Rependent Processing in a set of the state of Rependent Processing in a set of the state of Rependent Processing in a set of the state of Rependent Processing in a set of the state of Rependent Processing in a set of the state of Rependent Processing in a set of the state of Rependent Processing in a set of the state of Rependent Processing in a set of the state of Rependent Processing in a set of the state of Rependent Processing in a set of Representation of Rependent Processing in a set of Rependent Processing in a set of Rependent Processing in a set of Representation Processing in a set of Rependent Processing	Public reporting burden for this data needed, and completing ar	collection of information is es id reviewing this collection of	timated to average 1 hour per resp information. Send comments reg	oonse, including the time for revie arding this burden estimate or an	ewing instructions, sear	ching existing data sources, gathering and maintaining the ollection of information, including suggestions for reducing
Cald Out assessments       FLESS OD FOR FULUN TO A DOWN TO THE ASSY ADDRESS.       3. DATES COVERED         1. REPORT DATE       A INITUAL REPORT TYPE       3. DATES COVERED         1. JULY 20118       A INITUAL REPORT TYPE       1. JULY 2017 30. June 2018         4. TITLE AND SUBTIFIE       CONTRACT NUMBER         Control of Lung Inflammation by Microbiome and Peptidoglycan Recognition Protein       5. GRANT NUMBER         6. AUTHOR(S)       5. PROGRAM ELEMENT NUMBER         6. AUTHOR(S)       5. PROCRAM ELEMENT NUMBER         6. AUTHOR(S)       5. PROFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)         7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)       10. SPONSOR/MONITOR'S ACRONYM(S)         9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)       10. SPONSOR/MONITOR'S ACRONYM(S)         11. SPONSOR/MONITORING AGENCY NAME(S) AND ADDRESS(ES)       10. SPONSOR/MONITOR'S ACRONYM(S)         12. DISTRIBUTION / AVAILABILITY STATEMENT       Approved for Public Release; Distribution Unlimited         13. SUPPLEMENTARY NOTES       11. SPONSOR/MONITOR'S ACRONYM(S)         14. ABSTRACT       This project is using a mouse model of experimentally-induced asthma to test two hypotheses: (i) that respiratory and intestinal microbiones control sensitivity to asthma, and (ii) that this microbiome is controlled by antiAccretal innate immunity protein, proteody of microbions similary Otonia, similary Otonia similary Otonia, Proteodiect in microbiomes ison mild-type mice, as measured by lung resistanc	this burden to Department of De	efense, Washington Headqua	rters Services, Directorate for Info	rmation Operations and Reports	(0704-0188), 1215 Jeff for failing to comply wit	erson Davis Highway, Suite 1204, Arlington, VA 22202-
1. REPORT DATE       2. REPORT TYPE       3. DATES COVERED         1. UIV 2018       Annual Report       1. July 2017 – 30. June 2018         4. TITLE AND SUBTITLE       1. July 2017 – 30. June 2018         6. AUTHOR(S)       56. GRANT NUMBER         Bo. GRANT NUMBER       56. GRANT NUMBER         Bo. GRANT AUMBER       56. GRANT NUMBER         Bo. GRANT AUMBER       56. GRANT NUMBER         Bo. GRANT AUMBER       56. GRANT AUMBER         Bo. GRANT AUMBER       56. GRANT AUMBER         Bo. GRANT AUMBER       56. GRANT AUMBER         E-Mail: rdziar@jun.edu       57. WORK UNIT NUMBER         F. PERFORMING ORGANIZATION NAME(B) AND ADDRESS(ES)       10. SPONSORIMONITOR'S ACRONYM(S)         U.S. Army Medical Research and Materiel Command       6. PERFORMING ORGANIZATION REPORT         Fort Detrick, Maryland 21702-5012       11. SPONSOR/MONITOR'S REPORT         12. DISTRIBUTION / AVAILABILITY STATEMENT       Approved for Public Release; Distribution Unlimited         13. SUPPLEMENTARY NOTES       11. SPONSOR/MONITOR'S REPORT         14. ABSTRACT       This proportil sing a mouse model of experimentally-induced asthma to test two hypothese: (i) that respiratory and intestinal microbiones from Pay/pr/-deficient mice to the antibiotics and pregnant famales and their pups were colonized with microbiones from Pay/pr/-deficient mice. These pups were then sensitized, thad significantion, informatory, sinmary obtains t	valid OMB control number. PLE	ASE DO NOT RETURN YO	UR FORM TO THE ABOVE ADD	RESS.	ion realing to comply int	
J.I.IV.2013 B. JANUAL REDOT       11. Daty 2017 - 30 June 2018         ATTLE AND SUBSTIFIE       5. CONTRACT NUMBER         Control of Lung Inflammation by Microbiome and Peptidoglycan Recognition Protein       5. GRANT NUMBER         6. AUTHOR(S)       5. GRANT NUMBER         6. AUTHOR(S)       5. PROJECT NUMBER         6. AUTHOR(S)       5. PROJECT NUMBER         7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)       5. PROFORMING ORGANIZATION REPORT         7. PROFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)       5. PROFORMING ORGANIZATION REPORT         7. PROFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)       10. SPONSORMONITOR'S ACRONYM(S)         9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)       10. SPONSORMONITOR'S ACRONYM(S)         11. SPONSORMONITORING AGENCY NAME(S) AND ADDRESS(ES)       10. SPONSORMONITOR'S ACRONYM(S)         12. DISTRIBUTION / AVAILABILITY STATEMENT       7. PROFORMING RECognition (Trains and the interview of the section of the sec	1. REPORT DATE		2. REPORT TYPE		3. [	DATES COVERED
A. ITTLE AND SUBTILE     Control of Lung Inflammation by Microbiome and Peptidoglycan Recognition Protein     ab. CON IRCCI NUMBER     ab. CON IRCI NUMBER     ab. CON IRCI NUMBER     ab. CON IRCI NUMBER     ab. CON IRCCI NUMBER     ab. CON IRCCI NUMBER     ab. CON IRCI NUMBER     ab. CON IRCCI NUMBER     ab. CON IRCCI NUMBER     ab. CON IRCI NUMBER	July 2018	_	Annual Report		1	July 2017 - 30 June 2018
Control of Lung Initialization by Microbione and PepidoogyCan Recognition Protein	4. IIILE AND SUBIII	.E ommotion by Mio	rabiama and Dantida	alveen Decognition	Drotoin	CONTRACT NUMBER
B. GRAM MUBBER     WUBBER     WORLXVH-16-1-0230     Sc. PROGRAM ELEMENT NUMBER     Sc. PROGRAM ELEMENT NUMBER     Sc. PROGRAM ELEMENT NUMBER     Sc. TASK NUMER     Sc. TASK NUMER     Sc. TASK NUMER     Sc. TASK NUMER	Control of Lung Init	ammation by Mic	robiome and Peptido	giycan Recognition	Protein	
6. AUTHOR(S)         5d. PROJECT NUMBER           7. PERFORME CLEMENT NUMBER         5d. TASK NUMBER           7. PERFORME ORGANIZATION NAME(S) AND ADDRESS(ES)         5f. WORK UNIT NUMBER           7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)         10. SPONSORIMONITOR'S ACRONYM(S)           9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)         10. SPONSOR/MONITOR'S ACRONYM(S)           12. SATMY MEDICAL AGENCY NAME(S) AND ADDRESS(ES)         11. SPONSOR/MONITOR'S ACRONYM(S)           13. SUPPLEMENTARY MOTES         11. SPONSOR/MONITOR'S REPORT NUMBER(S)           14. ASSTRACT         This project is using a mouse model of experimentally-induced asthma to test two hypotheses: (i) that respiratory and intestinal microfloris for or form Pytyper - deficient mice. These pape were then sensitized with microfloras form wild-type in certoring spony cells. By contrast, gen-free mice (completely devid of microflora), similarly colonizad with microfloras from wild-type ince, as measured by lung resistance test and exten to i militoria were colonized with microfloras from wild-type or Pytyp-deficient mice ad sensitized with microfloras from wild-type or Pytyp-deficient mice ad sensitized with microfloras from wild-type or the sensitical with inflammatory cells. These results indicate that microflores from Pytype-1 with inflammatory cells. These results indicate that microflores from wild-type mice, as measured by lung resistance test and exten to i militrusony rele. Sensitivity to					5b.	
					VV	81XVVH-16-1-0230
6. AUTHOR(S) Roman Dziarski       5d. PROJECT NUMBER         F-Mail: rdziar@jun edu       5f. WORK UNIT NUMBER         7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)       8. PERFORMING ORGANIZATION REPORT NUMBER         7. DERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)       10. SPONSOR/MONITOR'S ACRONYM(S)         8. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)       10. SPONSOR/MONITOR'S ACRONYM(S)         12. STRIBUTION / MONITORING AGENCY NAME(S) AND ADDRESS(ES)       10. SPONSOR/MONITOR'S ACRONYM(S)         13. SUPPLEMENTARY NOTES       11. SPONSOR/MONITOR'S REPORT NUMBER(S)         14. ABSTRACT       This project is using a mouse model of experimentally-induced asthma to test two hypotheses: (1) that respiratory and intestinal microbiomes control sensitivity to asthma; and (ii) that this microbiome is controlled by antibacterial innau immunity protein. Peptidoglycan Recognition Protein 1 ( <i>Pglyrpl</i> ). Microflora was depleted in mice with antibiotics and pregnant females and their pups were colonized with microfloras from wild-type mice of from <i>Pglyrpl</i> - deficient mice. These pups were then sensitical with house dust mile allergen to induce asthma. Mice colonized with microfloras from wild type or <i>Pglyrpl</i> -deficient mice and sensitical, dad significantly less severe asthma and lung inflammation, as measured by lung resistance test and extent of infiltration with inflammatory cells. By contract, germ-free mice completely devold of microflora), similarly colonized with microbiomes from <i>Pglyrp1</i> - mice and sensitical, had significantly less severe and extent of infiltration with inflammatory cells. These results indicate that microbiome significantly affects sensitivity to asthma and lung inflammation as measur					5c.	PROGRAM ELEMENT NUMBER
6. AUTHOR(S)     ROMAN DZIATION NAME(S) AND ADDRESS(ES)     FERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)     T. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)     T. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)     S. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)     U. S. PONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)     U. S. Army Medical Research and Materiel Command     Fort Detrick, Maryland 21702-5012     U. SPONSOR/MONITOR'S ACRONYM(S)     U.S. Army Medical Research and Materiel Command     Fort Detrick, Maryland 21702-5012     U.S. Army Medical Research and Materiel Command     Fort Detrick, Maryland 21702-5012     U.S. Army Medical Research and Materiel Command     Fort Detrick Maryland 21702-1012     U.S. Army Medical Research and Materiel Command     Fort Detrick Maryland 21702-5012     U.S. Army Medical Research and Materiel Command     Fort Detrick Maryland 21702-5012     U.S. Army Medical Research and Materiel Command     Fort Detrick Maryland 21702-1012     U.S. Army Medical Research and Materiel Command     Fort Detrick Maryland 21702-5012     U.S. Army Medical Research and Materiel Command     Fort Detrick Maryland 21702-5012     U.S. Army Medical Research and Materiel Command     Fort Detrick Maryland 21702-5012     U.S. Army Medical Research and Materiel Command     Fort Detrick Maryland 21702-5012     U.S. Army Medical Research and Materiel Command     Fort Public Release; Distribution Unlimited     Is SUPPLEMENTARY NOTES     I.S. ARMY Maryland 21702-6012     U.S. Army Medical Research Market Mar						
ROMAN DZIARSKI       6. TASK NUMBER         E-Mail: rdziar@jun.edu       5. WORK UNIT NUMBER         7. PERFORMING ORGANIZATION NAME(6) AND ADDRESS(E5)       8. PERFORMING ORGANIZATION REPORT         7. NUMBER       9. SPONSORING / MONITORING AGENCY NAME(6) AND ADDRESS(E5)       10. SPONSOR/MONITOR'S ACRONYM(6)         9. SPONSORING / MONITORING AGENCY NAME(6) AND ADDRESS(ES)       10. SPONSOR/MONITOR'S ACRONYM(6)         12. SYNTY Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012       11. SPONSOR/MONITOR'S REPORT NUMBER(6)         12. DISTRIBUTION / AVAILABILITY STATEMENT       Approved for Public Release; Distribution Unlimited         13. SUPPLEMENTARY NOTES       14. ABSTRACT         14. ABSTRACT       This project is using a mouse model of experimentally-induced astima to test two hypotheses: (i) that respiratory and intestinal microbiomes control legraphy D. Microflora was deplect in mice with antibiotics and programa (makes and theri paps were colonized with microfloras from wild-type mice or from Pg/pyPI-deficient mice. These pups were then sensitized with house dust mite allergen to induce astima. Mice colonized with microbiomes from Wg/type or Pg/typ-deficient mice had significantly less severity of asthma and lung inflammation as measure by lung resistance test and extend or infiltration with inflammatory cells. By contract, germ-free mice colonized with microfloras from wild-type mice, as measured by lung resistance test and extend or infiltration with inflammatory cells. These results indicate that microbiome significantly affects sensitivity to asthma and lung inflammation and han germ-free mice colonized with microbiomes from Pg/typT - Timice and sens	6. AUTHOR(S)				5d.	PROJECT NUMBER
5 TASK NUMBER         E-Mail: rdziar@jun edu         7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)         TRUSTEES OF INDIANA UNIVERSITY. INDIANAPOLIS, IN 46202         9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)         U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012         10. SPONSOR/MONITOR'S ACRONYM(S)         12. DISTRIBUTION / AVAILABILITY STATEMENT         Approved for Public Release; Distribution Unlimited         13. SUPPLEMENTARY NOTES         14. ABSTRACT         This project is using a mouse model of experimentally-induced asthma to test two hypotheses: (i) that respiratory and intestinal microbiomes control is nosinitivity to asthma; and (ii) that this microbiome is controlled by antibacterial inate immunity protein. Peritodylexa estima. Mice colonized with microfors from Wid-type mice or from Pg/typ/-deficient mice. These pups were then essnitized with house dust mit ecompletely devid of microflora, jsimilarly colonized with microbiomes from Wid-type mice, as measured by lung resistance test and extent of infiltration with inflammatory cells. These results indicate that microbiomes from wild-type mice, as measured by lung resistance test and extent of infiltration with inflammatory cells. These results indicate hat microbiomes from Wid-type mice, as measured by lung resistance test and extent of infiltration with inflammatory cells. These results indicate that microbiomes from Wid-type mice, as measured by lung resistance test and extent of infiltration with inflammatory cells. These results indicate that microbiomes from Wid-type mice, as measured by lung resistance test and extent of infiltration with inflammatory cells. These	Roman Dziarski					
E-Mail: rdziar@iun.edu       5f. WORK UNIT NUMBER         7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)       8. PERFORMING ORGANIZATION REPORT         TRUSTEES OF INDIANA UNIVERSITY. INDIANAPOLIS, IN 46202       8. PERFORMING ORGANIZATION REPORT         9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)       10. SPONSOR/MONITOR'S ACRONYM(S)         U.S. Army Medical Research and Materiel Command       11. SPONSOR/MONITOR'S ACRONYM(S)         Fort Detrick, Maryland 21702-5012       11. SPONSOR/MONITOR'S REPORT         12. DISTRIBUTION / AVAILABILITY STATEMENT       NUMBER         Approved for Public Release; Distribution Unlimited       11. SPONSOR/MONITOR'S REPORT         13. SUPPLEMENTARY NOTES       5. MORE of the interview of the					5e.	TASK NUMBER
E-Mail: rdziar@jun.edu       5. WORK UNIT NUMBER         7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)       8. PERFORMING ORGANIZATION RAME(S) AND ADDRESS(ES)         TRUSTEES OF INDIANA UNIVERSITY. INDIANAPOLIS, IN 46202       8. PERFORMING ORGANIZATION REPORT         9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)       10. SPONSOR/MONITOR'S ACRONYM(S)         U.S. Army Medical Research and Materiel Command       11. SPONSOR/MONITOR'S ACRONYM(S)         Fort Detrick, Maryland 21702-5012       11. SPONSOR/MONITOR'S REPORT         12. DISTRIBUTION / AVAILABILITY STATEMENT       MUMBER         Approved for Public Release; Distribution Unlimited       13. SUPPLEMENTARY NOTES         14. ABSTRACT       This project is using a mouse model of experimentally-induced asthma to test two hypothese: (i) that respiratory and intestinal microbiome control sensitivity to asthma, and (ii) that this microbiome is controlled by antibacterial innate immunity protein, Peptidoglycan Recognition Protein 1 (Pg/byrp). Microflora was depleted in mice with antibiotics and prepanat females and their pups were colonized with microfloras from wild-type or Pg/byrp-deficient mice had similar severity of asthma and lung inflammation, as measured by lung resistance test and extent of infiltration with inflammatory cells. These results indicate that microbiomes from wild-type mice or 100 m Pg/byrp1-deficient mice and sensitive(1 ad significantly less severe easthma and lung inflammation than germ-free mice colonized with microbiomes from wild-type mice as measured by lung resistance test and extent of infiltration with inflammatory cells. These reseaults indicate that microbiomes from wild-type mice as meastred b						
E-Mail: rdziar@jun.edu       .         7. PERFORMING ORGANIZATION NAME(5) AND ADDRESS[ES]       8. PERFORMING ORGANIZATION REPORT         TRUSTEES OF INDIANA UNIVERSITY. INDIANAPOLIS. IN 46202       8. PERFORMING ORGANIZATION REPORT         9. SPONSORING / MONITORING AGENCY NAME(5) AND ADDRESS[ES]       10. SPONSOR/MONITOR'S ACRONYM(5)         U.S. Army Medical Research and Materiel Command       11. SPONSOR/MONITOR'S REPORT         Fort Detrick, Maryland 21702-5012       11. SPONSOR/MONITOR'S REPORT         12. DISTRIBUTION / AVAILABILITY STATEMENT       MUMBER(5)         Approved for Public Release; Distribution Unlimited       13. SUPPLEMENTARY NOTES         14. ABSTRACT       This project is using a mouse model of experimentally-induced asthma to test two hypotheses: (i) that respiratory and intestinal microbiome is controlled by antibacterial innaic immunity protein.         Peridoglycan Recognition Protein 1 ( <i>Pg/ny1</i> ). Microflora was depleted in mice with antibiotics and pregnant females and their pups were colonized with microbiomes from <i>Pg/ny1</i> -deficient mice. These pups were then assistized with house dust mite adlergen to induce asthma. Mice colonized with microbiomes from <i>Pg/ny1</i> -deficient mice had significantly less severe asthma and lung inflammation, as measured by lung resistance test and extent of infiltration with inflammatory response in the lungs compared with microbiomes from <i>Pg/ny1</i> -deficient mice adsensitivity to asthma and lung inflammation than germ-free mice colonized with microbiomes from wild-type mice.         16. SECURITY CLASSIFICATION OF:       17. LIMITATION OF ABSTRACT       18. NUMBER					5f.	WORK UNIT NUMBER
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)       8. PERFORMING ORGANIZATION REPORT         TRUSTEES OF INDIANA UNIVERSITY. INDIANAPOLIS. IN 46202       8. PERFORMING ORGANIZATION REPORT         9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)       10. SPONSOR/MONITOR'S ACRONYM(S)         U.S. Army Medical Research and Materiel Command       11. SPONSOR/MONITOR'S REPORT         Fort Detrick, Maryland 21702-5012       11. SPONSOR/MONITOR'S REPORT         12. DISTRIBUTION / AVAILABILITY STATEMENT       Approved for Public Release; Distribution Unlimited         13. SUPPLEMENTARY NOTES       13. SUPPLEMENTARY NOTES         14. ABSTRACT       This project is using a mouse model of experimentally-induced asthma to test two hypotheses: (i) that respiratory and intestinal microbiomes control sensitivity to asthma; and (ii) that this microbiome is controlled by antibacterial innait immunity protein, Peptidoglycan Recognition Protein 1 ( <i>Pglyrp1</i> ). Microflora was depleted in mice with antibiotics and pregnant females and their pups were colonized with microfloras from wild-type mice or from <i>Pglyrp2</i> -deficient mice. These pups were then sensitized with bouse dust mite allergen to induce asthma. Mice colonized with microfloras from Wild-type ince, as measured by lung resistance test and extent of infiltration with inflammatory cells. By contrast, germ-free mice (completely devid of microfloras), similarly cells. The contrast, germ-free mice (completely devid of microbiome from <i>Pglyrp1</i> -deficient mice response in the lungs compared with microbiome from wild-type mice, as measured by lung resistance test and extent of infiltration with inflammatory response in the lungs compared with microbiome from wild-type mice, as measure	E-Mail: rdziar@iun.	edu				
TRUSTEES OF INDIANA UNIVERSITY. INDIANAPOLIS. IN 46202       NUMBER         9. SPONSORING / MONITORING AGENCY NAME(\$) AND ADDRESS(E\$)       10. SPONSOR/MONITOR'S ACRONYM(\$)         U.S. Army Medical Research and Materiel Command       11. SPONSOR/MONITOR'S ACRONYM(\$)         Fort Detrick, Maryland 21702-5012       11. SPONSOR/MONITOR'S REPORT NUMBER(\$)         12. DISTRIBUTION / AVAILABILITY STATEMENT       Approved for Public Release; Distribution Unlimited         13. SUPPLEMENTARY NOTES       14. ABSTRACT         This project is using a mouse model of experimentally-induced asthma to test two hypotheses: (i) that respiratory and intestinal microbiomes control sensitivity to asthma; and (ii) that this microbiome is controlled by antibacterial innate immunity protein, Peptidoglycan Recognition Protein 1 (Pg/yPf). Microflora was depleted in mice with antibiotics and pregnant females and their pups were clononized with microfloras from wild-type or Pg/yp-deficient mice, as measured by lung resistance test and extent of influtation with microflora, similarly colonized with microfloras from Pg/yrp/1-deficient mice, as measured by lung resistance test and extent of influtation with microflora sessitis indicate that microbiomes significantly affects sensitivity to asthma and lung inflammation at measured by lung results indicate that microbiome significantly affects sensitivity to asthma and lung inflammation and that microbiome. Inome Pg/yrp1-deficient mice, as measured by lung resistance test and extent of influtation with inflammatory cells. These results indicate that microbiome significantly affects sensitive to asthma and lung inflammation and that microbiome from Pg/yrp1-deficient mice reduces allergic inflammatory response in the lungs compared with microbiome from wild-t	7. PERFORMING ORG	ANIZATION NAME(S	) AND ADDRESS(ES)		8. F	PERFORMING ORGANIZATION REPORT
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)       10. SPONSOR/MONITOR'S ACRONYM(S)         U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012       11. SPONSOR/MONITOR'S REPORT NUMBER(S)         12. DISTRIBUTION / AVAILABILITY STATEMENT         Approved for Public Release; Distribution Unlimited         13. SUPPLEMENTARY NOTES         14. ABSTRACT This project is using a mouse model of experimentally-induced asthma to test two hypotheses: (i) that respiratory and intestinal microbiomes control sensitivity to asthma; and (ii) that this microbiome is controlled by antibacterial innate immunity protein, Peptidoglycan Recognition Protein 1 ( <i>Pglymp1</i> ). Microflora was depleted in mice with antibiotics and pregnant females and their pups were colonized with microfloras from wild-type mice or from <i>Pglymp1</i> -deficient mice. These pups were then sensitized with house dust mite allergen to induce asthma. Mice colonized with microfloras from wild-type or <i>Pglymp2</i> -deficient mice. These pups were then sensitized, had significantly all service of asthma and lung inflammation, as measured by lung resistance test and extent of infiltration with inflammatory cells. Similarly colonized with microbiomes from <i>Pglymp1</i> -deficient mice reduces allergic inflammatory resonse in the lungs compared with microbiome from wild-type mice.         16. SUBJECT TERMS Asthma, Acute Lung Injury, Microbiome, Innate Immunity, Peptidoglycan Recognition Protein 1, Pglymp1	TRUSTEES OF I	NDIANA UNIVE	RSITY, INDIANAP	OLIS, IN 46202	1	NUMBER
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)       10. SPONSOR/MONITOR'S ACRONYM(S)         U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012       11. SPONSOR/MONITOR'S ACRONYM(S)         12. DISTRIBUTION / AVAILABILITY STATEMENT       11. SPONSOR/MONITOR'S REPORT NUMBER(S)         12. DISTRIBUTION / AVAILABILITY STATEMENT       Approved for Public Release; Distribution Unlimited         13. SUPPLEMENTARY NOTES       14. ABSTRACT         This project is using a mouse model of experimentally-induced asthma to test two hypotheses: (i) that respiratory and intestinal microbiomes control sensitivity to asthma; and (ii) that this microbiome is controlled by antibacterial innate immunity protein. Peptidoglycan Recognition Protein 1 (Pg/yrp1). Microflora was depleted in mice with antibiotics and pregnant females and their pups were colonized with microfloras from wild-type mice or from Pg/yrp1-deficient mice. These pups were then sensitized with house dust mite allergen to induce asthma. Mice colonized with microbiomes from Pg/yrp1-deficient mice had similar severity of asthma and lung inflammation, as measured by lung resistance test and extent of infiltration with inflammatory cells. By contrast, germ-free mice (completely devoid of microflora), similarly colonized with microbiomes from Pg/yrp1-deficient mice, as measured by lung resistance test and extent of infiltration with inflammatory cells. These results indicate that microbiome significantly alfects sensitivity to asthma and lung inflammation and that microbiome, Innate Immunity, Peptidoglycan Recognition Protein 1, Pg/yrp1         16. SUBJECT TERMS Asthma, Acute Lung Injury, Microbiome, Innate Immunity, Peptidoglycan Recognition Protein 1, Pg/yrp1						
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)       10. SPONSOR/MONITOR'S ACCONYM(S)         U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012       11. SPONSOR/MONITOR'S REPORT NUMBER(S)         12. DISTRIBUTION / AVAILABILITY STATEMENT       NUMBER(S)         Approved for Public Release; Distribution Unlimited       11. SPONSOR/MONITOR'S REPORT NUMBER(S)         13. SUPPLEMENTARY NOTES       14. ABSTRACT         This project is using a mouse model of experimentally-induced asthma to test two hypotheses: (i) that respiratory and intestinal microbiomes control sensitivity to asthma; and (ii) that this microbiome is controlled by antibacterial immate immunity protein, Peptidoglycan Recognition Protein 1 ( <i>Pg/nyr)</i> ). Microfora was depleted in mice with antibiotics and pregnant females and their pups were colonized with microfloras from wild-type or from <i>Pg/nyr)</i> -deficient mice. These pups were then sensitized, that summa and lung inflammation, as measured by lung resistance test and extent of infiltration with inflammatory cells. By contrast, germ-free mice (completely devoid of microflora), similarly colonized with microbiomes from <i>Pg/nyr</i> / <sup>1/*</sup> mice and sensitized, had significantly less severe and extent of infiltration with inflammatory cells. These results indicate that microbiome significantly affects sensitivity to asthma and lung inflammation and that microbiome from <i>Pg/nrp</i> /-deficient mice reduces allergic inflammatory response in the lungs compared with microbiome from wild-type mice.         16. SUBJECT TERMS Asthma, Acute Lung Injury, Microbiome, Innate Immunity, Peptidoglycan Recognition Protein 1, Pglyrp1       19a. NAME OF RESPONSIBLE PERSON USAMRMC       19a. TREPONS MARC / 19b. TELEPHONE NUMBER (mclude ar						
9. SPONSORING / MONITORING AGENCY NAME(\$) AND ADDRESS(E\$)       10. SPONSOR/MONITOR'S ACRONYM(\$)         U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012       11. SPONSOR/MONITOR'S REPORT NUMBER(\$)         12. DISTRIBUTION / AVAILABILITY STATEMENT         Approved for Public Release; Distribution Unlimited         13. SUPPLEMENTARY NOTES         14. ABSTRACT         This project is using a mouse model of experimentally-induced asthma to test two hypotheses: (i) that respiratory and intestinal microbiomes control sensitivity to asthma; and (ii) that this microbiome is controlled by antibacterial innate immunity protein, Peptidoglycan Recognition Protein 1 ( <i>Pglyrp1</i> ). Microflora was depleted in mice with antibiotics and pregnant females and their pups were colonized with microfloras from wild-type or <i>Pglyrp1</i> -deficient mice. These pups were the sensitized with mouse dust mite allergen to induce asthma. Mice colonized with microfloras from wild-type or <i>Pglyrp2</i> -deficient mice had similar servity of asthma and lung inflammation, as measured by lung resistance test and extent of inflitration with inflammatory cells. By contrast, germ-free mice (completely devoid of microflora), similarly colonized with microbiomes from <i>Pglyrp1</i> <sup>-//</sup> mice and sensitized, had significantly less severe asthma and lung inflammation than germ-free mice colonized with microbiome significantly affects sensitivity to asthma and lung inflammation and that microbiome from <i>Pglyrp1</i> -deficient mice reduces allergic inflammatory response in the lungs compared with microbiome from wild-type mice.         15. SUBJECT TERMS       17. LIMITATION OF ABSTRACT       18. NUMBER OF PAGES 10       19. NAME OF RESPONSIBLE PERSON USAIRMC						
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)       10. SPONSOR/MONITOR'S ACRONYM(S)         U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012       11. SPONSOR/MONITOR'S ACRONYM(S)         12. DISTRIBUTION / AVAILABILITY STATEMENT       11. SPONSOR/MONITOR'S REPORT NUMBER(S)         13. SUPPLEMENTARY NOTES       13. SUPPLEMENTARY NOTES         14. ABSTRACT       This project is using a mouse model of experimentally-induced asthma to test two hypotheses: (i) that respiratory and intestinal microbiomes control sensitivity to asthma; and (iii) that this microbiome is controlled by antibacterial innate immunity protein, Peptidoglycan Recognition Protein ( <i>Pgbyp1</i> ). Microflora was depleted in mice with antibiotics and pregnant females and their pups were colonized with microfloras from wild-type mice or from <i>Pgbyp1</i> - deficient mice. These pups were the sensitized with house dust mite allergen to induce asthma. Mice colonized with microfloras from <i>wild-type or Pgbyp2</i> -deficient mice and sensitized, had significantly less severe asthma and lung inflammation, as measured by lung resistance test and extent of infiltration with inflammatory cells. By contrast, germ-free mice (completely devoid of microflora), similarly colonized with microbiomes from <i>wld-type mice</i> , as measured by lung resistance test and extent of infiltration with inflammatory cells. These results indicate that microbiome significantly less severe asthma and lung inflammation and that microbiome from <i>Pglyrp1</i> -deficient mice reduces allergie inflammatory response in the lungs compared with microbiome from wild-type mice.         15. SUBJECT TERMS       17. LIMITATION OF ABSTRACT       18. NUMBER (P PAGES 10       19. TAMEC (PSPONSIBLE PERSON USAIRMC       19. TELEPHO						
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)       10. SPONSOR/MONITOR'S ACRONYM(S)         U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012       11. SPONSOR/MONITOR'S REPORT NUMBER(S)         12. DISTRIBUTION / AVAILABILITY STATEMENT       11. SPONSOR/MONITOR'S REPORT NUMBER(S)         13. SUPPLEMENTARY NOTES       13. SUPPLEMENTARY NOTES         14. ABSTRACT       This project is using a mouse model of experimentally-induced asthma to test two hypotheses: (i) that respiratory and intestinal microbiomes control sensitivity to asthma, and (ii) that this microbiome is controlled by antibacterial innate immunity protein, Peptidoglycan Recognition Protein 1 ( <i>Pglyrp1</i> ). Microflora was depleted in mice with antibiotics and pregnant females and their pups were colonized with microfloras from wild-type mice or from <i>Pglyrp1</i> -deficient mice. These pups were then sensitized with house dust mite allergen to induce asthma. Mice colonized with microfloras from wild-type or <i>Pglyrp1</i> -deficient mice had similar severity of asthma and lung inflammation, as measured by lung resistance test and extent of infiltration with inflammatory cells. By contrast, germ-free mice (completely devoid of microflora), similarly colonized with microbiomes from <i>Pglyrp1</i> - <sup>2-</sup> mice and sensitized, had significantly less severe asthma and lung inflammation than germ-free mice colonized with microbiome significantly affects sensitivity to asthma and lung inflammation and that microbiome from <i>Pglyrp1</i> -deficient mice reduces allergic inflammatory resonse in the lungs compared with microbiome from wild-type mice.         15. SUBJECT TERMS       Asthma, Acute Lung Injury, Microbiome, Innate Immunity, Peptidoglycan Recognition Protein 1, Pglyrp1         16. SECURITY						
U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012       11. SPONSOR/MONITOR'S REPORT NUMBER(S)         12. DISTRIBUTION / AVAILABILITY STATEMENT         Approved for Public Release; Distribution Unlimited         13. SUPPLEMENTARY NOTES         14. ABSTRACT This project is using a mouse model of experimentally-induced asthma to test two hypotheses: (i) that respiratory and intestinal microbiomes control sensitivity to asthma; and (ii) that this microbiome is controlled by antibacterial innate immunity protein, Peptidoglycan Recognition Protein 1 ( <i>Pglyp1</i> ). Microflora was depleted in mice with antibiotics and pregnant females and their pups were colonized with microfloras from wild-type or <i>Pglyp1</i> -deficient mice. These pups were then sensitized with house dust mite allergen to induce asthma. Mice colonized with microfloras from wild-type or <i>Pglyp1</i> <sup>-//</sup> mice and sensitized, had significantly less severe asthma and lung inflammation as measured by lung resistance test and extent of infiltration with inflammatory cells. By contrast, germ-free mice (completely devoid of microflora), similarly colonized with microbiomes from wild-type mice, as measured by lung resistance test and extent of infiltration with inflammatory cells. These results indicate that microbiome significantly affects sensitivity to asthma and lung inflammation and that microbiome from <i>Pglyp1</i> -deficient mice reduces allergic inflammatory response in the lungs compared with microbiome from wild-type mice.         15. SUBJECT TERMS Asthma, Acute Lung Injury, Microbiome, Innate Immunity, Peptidoglycan Recognition Protein 1, Pglyrp1         16. SECURITY CLASSIFICATION OF:       17. LIMITATION OF ABSTRACT 18       18. NUMBER (notwee aree cooply)	9. SPONSORING / MO	NITORING AGENCY	NAME(S) AND ADDRES	S(ES)	10.	SPONSOR/MONITOR'S ACRONYM(S)
U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012						
Fort Detrick, Maryland 21702-5012       11. SPONSOR/MONITOR'S REPORT NUMBER(S)         12. DISTRIBUTION / AVAILABILITY STATEMENT         Approved for Public Release; Distribution Unlimited         13. SUPPLEMENTARY NOTES         14. ABSTRACT         This project is using a mouse model of experimentally-induced asthma to test two hypotheses: (i) that respiratory and intestinal microbiomes control sensitivity to asthma; and (ii) that this microbiome is controlled by antibacterial innate immunity protein, Peptidoglycan Recognition Protein 1 ( <i>Pglyrp1</i> ). Microflora was depleted in mice with antibiotics and pregnant females and their pups were colonized with microfloras from wild-type or <i>Pglyrp1</i> -deficient mice. These pups were then sensitized with house dust mite allergen to induce asthma. Mice colonized with microfloras from wild-type or <i>Pglyrp1</i> -deficient mice. These pups were then sensitized with house dust mite allergen to induce asthma. Mice colonized with microfloras from wild-type or <i>Pglyrp1</i> -deficient mice, bay contrast, germ-free mice (completely devoid of microflora), similarly colonized with microbiomes from <i>Pglyrp1</i> - <sup>1/5</sup> mice and sensitized, had significantly less severe asthma and lung inflammation than germ-free mice colonized with microbiomes from <i>Pglyrp1</i> - <sup>1/5</sup> mice and sensitivity to asthma and lung inflammation than germ-free mice colonized with microbiomes from wild-type mice, as measured by lung resistance test and extent of infiltration with inflammatory cells. These results indicate that microbiome significantly affects sensitivity to asthma and lung inflammation and that microbiome from <i>Pglyrp1</i> -deficient mice reduces allergic inflammatory response in the lungs compared with microflores from wild-type mice.         15. SUBJECT TERMS       17. LIMITATION OF ABSTRACT       19.	U.S. Army Medical	Research and Ma	ateriel Command			
12. DISTRIBUTION / AVAILABILITY STATEMENT         Approved for Public Release; Distribution Unlimited         13. SUPPLEMENTARY NOTES         14. ABSTRACT         This project is using a mouse model of experimentally-induced asthma to test two hypotheses: (i) that respiratory and intestinal microbiomes control sensitivity to asthma; and (ii) that this microbiome is controlled by antibacterial innate immunity protein, Peptidoglycan Recognition Protein 1 ( <i>Pglyrp1</i> ). Microflora was depleted in mice with antibiotics and pregnant females and their pups were colonized with microfloras from wild-type mice or from <i>Pglyrp1</i> -deficient mice. These pups were then sensitized with house dust mite allergen to induce asthma. Mice colonized with microbiomes from <i>Pglyrp1</i> -deficient mice and sensitized, had significantly less severe asthma and lung inflammation and that microbiome from <i>Pglyrp1</i> -deficient mice reduces allergic inflammatory response in the lungs compared with microbiome from <i>Pglyrp1</i> -deficient mice reduces allergic inflammatory response in the lungs compared with microbiome from wild-type mice.         15. SUBJECT TERMS         Asthma, Acute Lung Injury, Microbiome, Innate Immunity, Peptidoglycan Recognition Protein 1, Pglyrp1         16. SECURITY CLASSIFICATION OF:       17. LIMITATION OF ABSTRACT       18. NUMBER 19. NUMBER (include area         18       Unclassified       19a. NAME OF RESPONSIBLE PERSON	Fort Detrick Maryla	and 21702-5012			11.	SPONSOR/MONITOR'S REPORT
12. DISTRIBUTION / AVAILABILITY STATEMENT         Approved for Public Release; Distribution Unlimited         13. SUPPLEMENTARY NOTES         14. ABSTRACT         This project is using a mouse model of experimentally-induced asthma to test two hypotheses: (i) that respiratory and intestinal microbiomes control sensitivity to asthma; and (ii) that this microbiome is controlled by antibacterial innate immunity protein, Peptidoglycan Recognition Protein 1 ( <i>Pglyrp1</i> ). Microflora was depleted in mice with antibiotics and pregnant females and their pups were colonized with microfloras from wild-type mice or from <i>Pglyrp1</i> -deficient mice. These pups were then sensitized with house dust mite allergen to induce asthma. Mice colonized with microfloras from wild-type or <i>Pglyrp1</i> -deficient mice. By contrast, germ-free mice (completely devoid of microflora), similarly colonized with microbiomes from <i>Pglyrp1</i> - <sup>-/-</sup> mice and sensitized, had significantly less severe asthma and lung inflammatory cells. These results indicate that microbiomes inform wild-type mice, as measured by lung resistance test and extent of infiltration with inflammatory cells. These results indicate that microbiomes infine with affects sensitivity to asthma and lung inflammator with inflammatory cells. These results indicate that microbiomes infine with affects sensitivity to asthma and lung inflammator match with informatory cells. These results indicate that microbiomes infine with affects sensitivity to asthma and lung inflammatory cells. These results indicate that microbiomes infine the ups compared with microbiome from wild-type mice.         15. SUBJECT TERMS         Asthma, Acute Lung Injury, Microbiome, Innate Immunity, Peptidoglycan Recognition Protein 1, Pglyrp1         16. SECURITY CLASSIFICATION OF:       17. LIMITATION						NUMBER(S)
12. DISTRIBUTION / AVAILABILITY STATEMENT         Approved for Public Release; Distribution Unlimited         13. SUPPLEMENTARY NOTES         14. ABSTRACT         This project is using a mouse model of experimentally-induced asthma to test two hypotheses: (i) that respiratory and intestinal microbiomes control sensitivity to asthma; and (ii) that this microbiome is controlled by antibacterial innate immunity protein, Peptidoglycan Recognition Protein 1 ( <i>Pglyrp1</i> ). Microflora was depleted in mice with antibiotics and pregnant females and their pups were colonized with microfloras from wild-type mice or from <i>Pglyrp1</i> -deficient mice. These pups were then sensitized with house dust mite allergen to induce asthma. Mice colonized with microfloras from wild-type or <i>Pglyrp1</i> -fr mice and sensitized, had significantly less severe asthma and lung inflammation as measured by lung resistance test and extent of infiltration with inflammatory cells. By contrast, germ-free mice (completely devoid of microflora), similarly colonized with microbiomes from <i>Wild-type mice</i> , as measured by lung resistance test and extent of infiltration with inflammatory cells. These results indicate that microbiomes from <i>Wild-type</i> mice, as measured by lung resistance test and extent of infiltration with inflammatory cells. These results indicate that microbiome significantly affects sensitivity to asthma and lung inflammation than germ-free mice reduces allergic inflammatory response in the lungs compared with microbiome from wild-type mice.         15. SUBJECT TERMS       17. LIMITATION of Asstract       18. NUMBER       19. NAME OF RESPONSIBLE PERSON USAMRMC         16. SECURITY CLASSIFICATION OF:       17. LIMITATION of Asstract       18. NUMBER       19. NAME OF RESPONSIBLE PERSON USAMRMC <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>						
Approved for Public Release; Distribution Unlimited         13. SUPPLEMENTARY NOTES         14. ABSTRACT         This project is using a mouse model of experimentally-induced asthma to test two hypotheses: (i) that respiratory and intestinal microbiomes control sensitivity to asthma; and (ii) that this microbiome is controlled by antibacterial innate immunity protein, Peptidoglycan Recognition Protein 1 (Pglyrp1). Microflora was depleted in mice with antibiotics and pregnant females and their pups were colonized with microfloras from wild-type mice or from Pglyrp1-deficient mice. These pups were then sensitized with house dust mite allergen to induce asthma. Mice colonized with microfloras from wild-type or Pglyrp1-deficient mice had similar severity of asthma and lung inflammation, as measured by lung resistance test and extent of infiltration with inflammatory cells. By contrast, gern-free mice (completely devoid of microflora), similarly colonized with microbiomes from Pglyrp1 <sup>-/-</sup> mice and sensitized, had significantly less severe asthma and lung inflammation than germ-free mice colonized with microbiomes from wild-type mice, as measured by lung resistance test and extent of infiltration with inflammatory cells. These results indicate that microbiome significantly affects sensitivity to asthma and lung inflammation and that microbiome, Innate Immunity, Peptidoglycan Recognition Protein 1, Pglyrp1         16. SUBJECT TERMS         Asthma, Acute Lung Injury, Microbiome, Innate Immunity, Peptidoglycan Recognition Protein 1, Pglyrp1         16. SECURITY CLASSIFICATION OF:       17. LIMITATION OF ABSTRACT       19. AMBE OF RESPONSIBLE PERSON USAMRMC         18       19. AMBER (include area code)       19. TLEPHONE NUMBER (include area code)   <	12 DISTRIBUTION / A	AII ABII ITY STATE	MENT			
Approved for Public Release; Distribution Unlimited         13. SUPPLEMENTARY NOTES         14. ABSTRACT         This project is using a mouse model of experimentally-induced asthma to test two hypotheses: (i) that respiratory and intestinal microbiomes control sensitivity to asthma; and (ii) that this microbiome is controlled by antibacterial innate immunity protein, Peptidoglycan Recognition Protein 1 ( <i>Pglyrp1</i> ). Microflora was depleted in mice with antibiotics and pregnant females and their pups were colonized with microfloras from wild-type or <i>Pglyrp1</i> -deficient mice. These pups were then sensitized with house dust mite allergen to induce asthma. Mice colonized with microfloras from wild-type or <i>Pglyrp1</i> -deficient mice had similar severity of asthma and lung inflammation, as measured by lung resistance test and extent of infiltration with inflammatory cells. By contrast, germ-free mice (completely devoid of microflora), similarly colonized with microbiomes from <i>Pglyrp1</i> - <sup>1</sup> mice and sensitized, had significantly less severe asthma and lung inflammation than germ-free mice colonized with microbiomes from wild-type mice, as measured by lung resistance test and extent of infiltration with inflammatory cells. These results indicate that microbiome significantly affects sensitivity to asthma and lung inflammation and that microbiome, Innate Immunity, Peptidoglycan Recognition Protein 1, Pglyrp1   16. SUBJECT TERMS   Asthma, Acute Lung Injury, Microbiome, Innate Immunity, Peptidoglycan Recognition Protein 1, Pglyrp1   16. SECURITY CLASSIFICATION OF:   17. LIMITATION   18. NUMBER   19. ABSTRACT   1. BASTRACT   1. BASTRACT   1. BASTRACT   1. BASTRACT						
13. SUPPLEMENTARY NOTES         14. ABSTRACT         This project is using a mouse model of experimentally-induced asthma to test two hypotheses: (i) that respiratory and intestinal microbiomes control sensitivity to asthma; and (ii) that this microbiome is controlled by antibacterial innate immunity protein, Peptidoglycan Recognition Protein 1 ( <i>Pglyrp1</i> ). Microflora was depleted in mice with antibiotics and pregnant females and their pups were colonized with microfloras from <i>Pglyrp1</i> -deficient mice. These pups were then sensitized with house dust mite allergen to induce asthma. Mice colonized with microfloras from wild-type or <i>Pglyrp1</i> -deficient mice ad similar severity of asthma and lung inflammation, as measured by lung resistance test and extent of infiltration with inflammatory cells. By contrast, germ-free mice (completely devoid of microflora), similarly colonized with microbiomes from <i>Pglyrp1</i> <sup>-/-</sup> mice and sensitized, had significantly less severe asthma and lung inflammation than germ-free mice colonized with microbiomes from <i>Pglyrp1</i> <sup>-/-</sup> mice and sensitized, had significantly less severe asthma and lung inflammatory cells. These results indicate that microbiome significantly affects sensitivity to asthma and lung inflammation and that microbiome from <i>Pglyrp1</i> -deficient mice reduces allergic inflammatory response in the lungs compared with microbiome from wild-type mice.         15. SUBJECT TERMS         Asthma, Acute Lung Injury, Microbiome, Innate Immunity, Peptidoglycan Recognition Protein 1, Pglyrp1         16. SECURITY CLASSIFICATION OF:       17. LIMITATION OF ABSTRACT         18       19a. NAME OF RESPONSIBLE PERSON USAMRMC         18       19b. TELEPHONE NUMBER (include area code)	Approved for Public	c Release: Distrib	ution Unlimited			
13. SUPPLEMENTARY NOTES         14. ABSTRACT This project is using a mouse model of experimentally-induced asthma to test two hypotheses: (i) that respiratory and intestinal microbiomes control sensitivity to asthma; and (ii) that this microbiome is controlled by antibacterial innate immunity protein, Peptidoglycan Recognition Protein 1 ( <i>Pglyrp1</i> ). Microflora was depleted in mice with antibiotics and pregnant females and their pups were colonized with microfloras from <i>Pglyrp1</i> -deficient mice. These pups were then sensitized with house dust mite allergen to induce asthma. Mice colonized with microfloras from wild-type or <i>Pglyrp-4</i> -deficient mice had similar severity of asthma and lung inflammation, as measured by lung resistance test and extent of infiltration with inflammatory cells. By contrast, germ-free mice (completely devoid of microflora), similarly colonized with microbiomes from <i>Pglyrp1</i> <sup>-//</sup> mice and sensitized, had significantly less severe asthma and lung inflammation than germ-free mice colonized with microbiomes from <i>Pglyrp1</i> <sup>-///</sup> mice and sensitized, had significantly less severe asthma and hung inflammation than germ-free mice colonized with microbiomes from wild-type mice, as measured by lung resistance test and extent of infiltration with inflammatory cells. These results indicate that microbiome significantly affects sensitivity to asthma and lung inflammation and that microbiome from <i>Pglyrp1</i> -deficient mice reduces allergic inflammatory response in the lungs compared with microbiome from wild-type mice.         15. SUBJECT TERMS         Asthma, Acute Lung Injury, Microbiome, Innate Immunity, Peptidoglycan Recognition Protein 1, Pglyrp1         16. SECURITY CLASSIFICATION OF:       17. LIMITATION OF ABSTRACT       18. NUMBER OF RESPONSIBLE PERSON USAMRMC         18. REPORT       b. ABSTRACT						
13. SUPPLEMENTARY NOTES         14. ABSTRACT         This project is using a mouse model of experimentally-induced asthma to test two hypotheses: (i) that respiratory and intestinal microbiomes control sensitivity to asthma; and (ii) that this microbiome is controlled by antibacterial innate immunity protein, Peptidoglycan Recognition Protein 1 ( <i>Pglyrp1</i> ). Microflora was depleted in mice with antibiotics and pregnant females and their pups were colonized with microfloras from wild-type mice or from <i>Pglyrp1</i> -deficient mice. These pups were then sensitized with house dust mite allergen to induce asthma. Mice colonized with microfloras from wild-type or <i>Pglyrp</i> -deficient mice had similar severity of asthma and lung inflammation, as measured by lung resistance test and extent of infiltration with inflammatory cells. By contrast, germ-free mice (completely devoid of microflora), similarly colonized with microbiomes from <i>Pglyrp1</i> <sup>-/-</sup> mice and sensitized, had significantly less severe asthma and lung inflammation than germ-free mice colonized with microbiomes from <i>Pglyrp1</i> <sup>-/-</sup> mice and sensitized, had significantly less severe asthma and lung inflammation with inflammatory cells. These results indicate that microbiome significantly affects sensitivity to asthma and lung inflammation and that microbiome from <i>Pglyrp1</i> -deficient mice reduces allergic inflammatory response in the lungs compared with microbiome from wild-type mice.         15. SUBJECT TERMS       Asthma, Acute Lung Injury, Microbiome, Innate Immunity, Peptidoglycan Recognition Protein 1, Pglyrp1         16. SECURITY CLASSIFICATION OF:       17. LIMITATION OF ABSTRACT       18. NUMBER OF RESPONSIBLE PERSON USAMRMC       19a. NAME OF RESPONSIBLE PERSON USAMRMC       19a. NAME OF RESPONSIBLE (include area code)						
14. ABSTRACT         This project is using a mouse model of experimentally-induced asthma to test two hypotheses: (i) that respiratory and intestinal microbiomes control sensitivity to asthma; and (ii) that this microbiome is controlled by antibacterial innate immunity protein, Peptidoglycan Recognition Protein 1 ( <i>Pglyrp1</i> ). Microflora was depleted in mice with antibiotics and pregnant females and their pups were colonized with microfloras from wild-type mice or from <i>Pglyrp1</i> -deficient mice. These pups were then sensitized with house dust mite allergen to induce asthma. Mice colonized with microfloras from wild-type or <i>Pglyrp</i> -deficient mice had similar severity of asthma and lung inflammation, as measured by lung resistance test and extent of infiltration with inflammatory cells. By contrast, germ-free mice (completely devoid of microflora), similarly colonized with microbiomes from <i>Pglyrp1</i> <sup>-/-</sup> mice and sensitized, had significantly less severe asthma and lung inflammation than germ-free mice colonized with microbiomes from wild-type mice, as measured by lung resistance test and extent of infiltration with inflammatory cells. These results indicate that microbiome significantly affects sensitivity to asthma and lung inflammation and that microbiome from <i>Pglyrp1</i> -deficient mice reduces allergic inflammatory response in the lungs compared with microbiome from wild-type mice.         16. SUBJECT TERMS         Asthma, Acute Lung Injury, Microbiome, Innate Immunity, Peptidoglycan Recognition Protein 1, Pglyrp1         16. SECURITY CLASSIFICATION OF:       17. LIMITATION OF ABSTRACT       18. NUMBER OF RESPONSIBLE PERSON USAMRMC         18. REPORT       b. ABSTRACT       c. THIS PAGE       19. TLEPHONE NUMBER (include area code)		NOTES				
14. ABSTRACT         This project is using a mouse model of experimentally-induced asthma to test two hypotheses: (i) that respiratory and intestinal microbiomes control sensitivity to asthma; and (ii) that this microbiome is controlled by antibacterial innate immunity protein, Peptidoglycan Recognition Protein 1 ( <i>Pglyrp1</i> ). Microflora was depleted in mice with antibiotics and pregnant females and their pups were colonized with microfloras from wild-type or <i>Pglyrp1</i> -deficient mice. These pups were then sensitized with house dust mite allergen to induce asthma. Mice colonized with microfloras from wild-type or <i>Pglyrp1</i> -deficient mice had similar severity of asthma and lung inflammation, as measured by lung resistance test and extent of infiltration with inflammatory cells. By contrast, germ-free mice (completely devoid of microflora), similarly colonized with microbiomes from <i>Pglyrp1</i> <sup>-/-</sup> mice and sensitized, had significantly less severe asthma and lung inflammation than germ-free mice colonized with microbiomes from <i>wlld</i> -type mice, as measured by lung resistance test and extent of infiltration with inflammatory cells. These results indicate that microbiome significantly affects sensitivity to asthma and lung inflammation and that microbiome from <i>Pglyrp1</i> -deficient mice reduces allergic inflammatory response in the lungs compared with microbiome from wild-type mice.         15. SUBJECT TERMS         Asthma, Acute Lung Injury, Microbiome, Innate Immunity, Peptidoglycan Recognition Protein 1, Pglyrp1         16. SECURITY CLASSIFICATION OF:       17. LIMITATION OF ABSTRACT       18. NUMBER OF RESPONSIBLE PERSON USAMRMC         18. REPORT       b. ABSTRACT       c. THIS PAGE       18. NUMBER OF RESPONSIBLE PERSON USAMRMC	IS. SOFFELMENTAN	NOTES				
14. ABSTRACT         This project is using a mouse model of experimentally-induced asthma to test two hypotheses: (i) that respiratory and intestinal microbiomes control sensitivity to asthma; and (ii) that this microbiome is controlled by antibacterial innate immunity protein, Peptidoglycan Recognition Protein 1 ( <i>Pglyrp1</i> ). Microflora was depleted in mice with antibiotics and pregnant females and their pups were colonized with microfloras from wild-type mice or from <i>Pglyrp1</i> -deficient mice. These pups were then sensitized with house dust mite allergen to induce asthma. Mice colonized with microfloras from wild-type or <i>Pglyrp1</i> -deficient mice test and extent of infiltration with inflammatory cells. By contrast, germ-free mice (completely devoid of microflora), similarly colonized with microbiomes from <i>Pglyrp1</i> <sup>-/-</sup> mice and sensitized, had significantly less severe asthma and lung inflammation than germ-free mice colonized with microbiomes from <i>Pglyrp1</i> <sup>-/-</sup> mice and sensitized, as measured by lung resistance test and extent of infiltration with inflammatory cells. These results indicate that microbiome significantly affects sensitivity to asthma and lung inflammation and that microbiome from <i>Pglyrp1</i> -deficient mice reduces allergic inflammatory response in the lungs compared with microbiome from wild-type mice.         15. SUBJECT TERMS         Asthma, Acute Lung Injury, Microbiome, Innate Immunity, Peptidoglycan Recognition Protein 1, Pglyrp1         16. SECURITY CLASSIFICATION OF:         a. REPORT       b. ABSTRACT         c. THIS PAGE       17. LIMITATION OF ABSTRACT         18       19a. NAME OF RESPONSIBLE PERSON USAMRMC         19b. TELEPHONE NUMBER (include area code)						
14. ABSTRACT         This project is using a mouse model of experimentally-induced asthma to test two hypotheses: (i) that respiratory and intestinal microbiomes control sensitivity to asthma; and (ii) that this microbiome is controlled by antibacterial innate immunity protein, Peptidoglycan Recognition Protein 1 ( <i>Pglyrp1</i> ). Microflora was depleted in mice with antibiotics and pregnant females and their pups were colonized with microfloras from wild-type mice or from <i>Pglyrp1</i> -deficient mice. These pups were then sensitized with house dust mite allergen to induce asthma. Mice colonized with microfloras from wild-type or <i>Pglyrp</i> -deficient mice had similar severity of asthma and lung inflammation, as measured by lung resistance test and extent of infiltration with inflammatory cells. By contrast, germ-free mice (completely devoid of microflora), similarly colonized with microbiomes from <i>Pglyrp1</i> <sup>-/-</sup> mice and sensitized, had significantly less severe asthma and lung inflammation than germ-free mice colonized with microbiomes from <i>Pglyrp1</i> <sup>-/-</sup> mice and sensitized, had significantly less severe asthma and lung inflammation than germ-free mice colonized with microbiomes from wild-type mice, as measured by lung resistance test and extent of infiltration with inflammatory cells. These results indicate that microbiome significantly affects sensitivity to asthma and lung inflammation and that microbiome from <i>Pglyrp1</i> -deficient mice reduces allergic inflammatory response in the lungs compared with microbiome from wild-type mice.         15. SUBJECT TERMS         Asthma, Acute Lung Injury, Microbiome, Innate Immunity, Peptidoglycan Recognition Protein 1, Pglyrp1         16. SECURITY CLASSIFICATION OF:       17. LIMITATION OF ABSTRACT       18. NUMBER OF RESPONSIBLE PERSON USAMRMC         18. REPORT       b. ABSTRACT	44 40070407					
This project is using a mouse mode of experimentally-induced astima to test two hypotneses: (1) that respiratory and intestinal microbiomes control sensitivity to asthma; and (ii) that this microbiome is controlled by antibacterial innate immunity protein, Peptidoglycan Recognition Protein 1 ( <i>Pglyrp1</i> ). Microflora was depleted in mice with antibiotics and pregnant females and their pups were colonized with microfloras from wild-type mice or from <i>Pglyrp1</i> -deficient mice. These pups were then sensitized with house dust mite allergen to induce asthma. Mice colonized with microfloras from wild-type or <i>Pglyrp1</i> -deficient mice. These pups were that similar severity of asthma and lung inflammation, as measured by lung resistance test and extent of infiltration with inflammatory cells. By contrast, germ-free mice (completely devoid of microflora), similarly colonized with microbiomes from <i>Pglyrp1</i> <sup>-/-</sup> mice and sensitized, had significantly less severe asthma and lung inflammation than germ-free mice colonized with microbiomes from <i>Wglyrp1</i> <sup>-/-</sup> mice, as measured by lung resistance test and extent of infiltration with inflammatory cells. These results indicate that microbiome significantly affects sensitivity to asthma and lung inflammation and that microbiome from <i>Pglyrp1</i> -deficient mice reduces allergic inflammatory response in the lungs compared with microbiome from wild-type mice.         15. SUBJECT TERMS         Asthma, Acute Lung Injury, Microbiome, Innate Immunity, Peptidoglycan Recognition Protein 1, Pglyrp1         16. SECURITY CLASSIFICATION OF:       17. LIMITATION OF ABSTRACT       18. NUMBER OF RESPONSIBLE PERSON USAMRMC         18.       19a. NAME OF RESPONSIBLE PERSON USAMRMC       19b. TELEPHONE NUMBER (include area code)	14. ABSTRACT			Leadhaire de dead de la	and the second Child	d manimud and an 1 indeeding 1
microbiomes control sensitivity to astima; and (ii) that this microbiome is controlled by antibacterial innate immunity protein,         Peptidoglycan Recognition Protein 1 ( <i>Pglyrp1</i> ). Microflora was depleted in mice with antibiotics and pregnant females and their pups were colonized with microfloras from <i>Pglyrp1</i> -deficient mice. These pups were then sensitized with house dust mite allergen to induce asthma. Mice colonized with microfloras from wild-type or <i>Pglyrp</i> -deficient mice had similar severity of asthma and lung inflammation, as measured by lung resistance test and extent of infiltration with inflammatory cells. By contrast, germ-free mice (completely devoid of microflora), similarly colonized with microbiomes from <i>Pglyrp1</i> <sup>-/-/-</sup> mice and sensitized, had significantly less severe asthma and lung inflammation than germ-free mice colonized with microbiomes from wild-type mice, as measured by lung resistance test and extent of infiltration with inflammatory cells. These results indicate that microbiome significantly affects sensitivity to asthma and lung inflammation and that microbiome from <i>Pglyrp1</i> -deficient mice reduces allergic inflammatory response in the lungs compared with microbiome from wild-type mice.         16. SUBJECT TERMS         Asthma, Acute Lung Injury, Microbiome, Innate Immunity, Peptidoglycan Recognition Protein 1, Pglyrp1         16. SECURITY CLASSIFICATION OF:       17. LIMITATION OF ABSTRACT       18. NUMBER OF RESPONSIBLE PERSON USAMRMC         a. REPORT       b. ABSTRACT       c. THIS PAGE       18       Unclassified       19a. NAME OF RESPONSIBLE PERSON USAMRMC	This project is using	a mouse model of e	experimentally-induced	asthma to test two hy	potheses: (1) th	at respiratory and intestinal
Peptidoglycan Recognition Protein 1 ( <i>Pglyrp1</i> ). Microflora was depleted in mice with antibiotics and pregnant females and their pups were colonized with microfloras from <i>Pglyrp1</i> -deficient mice. These pups were then sensitized with house dust mite allergen to induce asthma. Mice colonized with microfloras from wild-type or <i>Pglyrp</i> -deficient mice had similar severity of asthma and lung inflammation, as measured by lung resistance test and extent of infiltration with inflammatory cells. By contrast, germ-free mice (completely devoid of microflora), similarly colonized with microbiomes from <i>Pglyrp1</i> <sup>-/-</sup> mice and sensitized, had significantly less severe asthma and lung inflammation than germ-free mice colonized with microbiomes from <i>Pglyrp1</i> <sup>-/-</sup> mice and sensitized, had significantly less severe asthma and lung inflammation with inflammatory cells. These results indicate that microbiome significantly affects sensitivity to asthma and lung inflammation and that microbiome from <i>Pglyrp1</i> -deficient mice reduces allergic inflammatory response in the lungs compared with microbiome from wild-type mice.         15. SUBJECT TERMS         Asthma, Acute Lung Injury, Microbiome, Innate Immunity, Peptidoglycan Recognition Protein 1, Pglyrp1         16. SECURITY CLASSIFICATION OF:       17. LIMITATION OF ABSTRACT       18. NUMBER OF RESPONSIBLE PERSON USAMRMC         a. REPORT       b. ABSTRACT       c. THIS PAGE       18.       19a. NAME OF RESPONSIBLE PERSON USAMRMC	microbiomes control	sensitivity to asthm	ha; and (11) that this mid	crobiome is controlled	by antibacteria	al innate immunity protein,
colonized with microfloras from wild-type mice or from Pglyrp1-deficient mice. These pups were then sensitized with house dust mite allergen to induce asthma. Mice colonized with microfloras from wild-type or Pglyrp-deficient mice had similar severity of asthma and lung inflammation, as measured by lung resistance test and extent of infiltration with inflammatory cells. By contrast, germ-free mice (completely devoid of microflora), similarly colonized with microbiomes from Pglyrp1-'- mice and sensitized, had significantly less severe asthma and lung inflammation than germ-free mice colonized with microbiomes from wild-type mice, as measured by lung resistance test and extent of infiltration with inflammatory cells. These results indicate that microbiome significantly affects sensitivity to asthma and lung inflammation and that microbiome from Pglyrp1-deficient mice reduces allergic inflammatory response in the lungs compared with microbiome from wild-type mice.15. SUBJECT TERMS Asthma, Acute Lung Injury, Microbiome, Innate Immunity, Peptidoglycan Recognition Protein 1, Pglyrp116. SECURITY CLASSIFICATION OF:17. LIMITATION OF ABSTRACT18. NUMBER OF PAGES 1819a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include area code)	Peptidoglycan Recog	nition Protein 1 ( $P_2$	<i>glyrp1</i> ). Microflora wa	s depleted in mice with	th antibiotics an	d pregnant females and their pups were
allergen to induce asthma. Mice colonized with microfloras from wild-type or <i>Pglyrp</i> -deficient mice had similar severity of asthma and lung inflammation, as measured by lung resistance test and extent of infiltration with inflammatory cells. By contrast, germ-free mice (completely devoid of microflora), similarly colonized with microbiomes from <i>Pglyrp1</i> <sup>-/-</sup> mice and sensitized, had significantly less severe asthma and lung inflammation than germ-free mice colonized with microbiomes from wild-type mice, as measured by lung resistance test and extent of infiltration with inflammatory cells. These results indicate that microbiome significantly affects sensitivity to asthma and lung inflammation and that microbiome from <i>Pglyrp1</i> -deficient mice reduces allergic inflammatory response in the lungs compared with microbiome from wild-type mice. <b>15. SUBJECT TERMS</b> Asthma, Acute Lung Injury, Microbiome, Innate Immunity, Peptidoglycan Recognition Protein 1, Pglyrp1 <b>16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 18. NUMBER 19a. NAME OF RESPONSIBLE PERSON USAMRMC 18. NUMBER 19b. TELEPHONE NUMBER</b> <i>(include area code)</i>	colonized with micro	floras from wild-ty	pe mice or from <i>Pglyr</i>	<i>p1</i> -deficient mice. The	ese pups were t	hen sensitized with house dust mite
lung inflammation, as measured by lung resistance test and extent of infiltration with inflammatory cells. By contrast, germ-free mice (completely devoid of microflora), similarly colonized with microbiomes from Pglyrp1 <sup>-/-</sup> mice and sensitized, had significantly less severe asthma and lung inflammation than germ-free mice colonized with microbiomes from wild-type mice, as measured by lung resistance test and extent of infiltration with inflammatory cells. These results indicate that microbiome significantly affects sensitivity to asthma and lung inflammation and that microbiome from Pglyrp1-deficient mice reduces allergic inflammatory response in the lungs compared with microbiome from wild-type mice.         15. SUBJECT TERMS         Asthma, Acute Lung Injury, Microbiome, Innate Immunity, Peptidoglycan Recognition Protein 1, Pglyrp1         16. SECURITY CLASSIFICATION OF:         a. REPORT       b. ABSTRACT         c. THIS PAGE       18         Unclassified       19b. TELEPHONE NUMBER (include area code)	allergen to induce ast	hma. Mice coloniz	ed with microfloras fro	om wild-type or Pglyr	<i>p</i> -deficient mice	e had similar severity of asthma and
(completely devoid of microflora), similarly colonized with microbiomes from $PglyrpI^{-/-}$ mice and sensitized, had significantly less severe asthma and lung inflammation than germ-free mice colonized with microbiomes from wild-type mice, as measured by lung resistance test and extent of infiltration with inflammatory cells. These results indicate that microbiome significantly affects sensitivity to asthma and lung inflammation and that microbiome from $Pglyrp1$ -deficient mice reduces allergic inflammatory response in the lungs compared with microbiome from wild-type mice.15. SUBJECT TERMS Asthma, Acute Lung Injury, Microbiome, Innate Immunity, Peptidoglycan Recognition Protein 1, Pglyrp116. SECURITY CLASSIFICATION OF:17. LIMITATION OF ABSTRACTa. REPORTb. ABSTRACTc. THIS PAGE17. LIMITATION OF ABSTRACT18. NUMBER OF PAGES19a. NAME OF RESPONSIBLE PERSON USAMRMCUnclassified	lung inflammation, a	s measured by lung	resistance test and ext	ent of infiltration with	n inflammatory	cells. By contrast, germ-free mice
asthma and lung inflammation than germ-free mice colonized with microbiomes from wild-type mice, as measured by lung resistance test and extent of infiltration with inflammatory cells. These results indicate that microbiome significantly affects sensitivity to asthma and lung inflammation and that microbiome from <i>Pglyrp1</i> -deficient mice reduces allergic inflammatory response in the lungs compared with microbiome from wild-type mice. <b>15. SUBJECT TERMS</b> Asthma, Acute Lung Injury, Microbiome, Innate Immunity, Peptidoglycan Recognition Protein 1, Pglyrp1 <b>16. SECURITY CLASSIFICATION OF: 17. LIMITATION</b> <b>0 F ABSTRACT 18. NUMBER</b> <b>0 F PAGES 19a. NAME OF RESPONSIBLE PERSON</b> <b>USAMRMC a. REPORT b. ABSTRACT c. THIS PAGE 18 19b. TELEPHONE NUMBER</b> <i>(include area code)</i>	(completely devoid o	f microflora), simil	arly colonized with mi	crobiomes from Pgly	<i>rp1<sup>-/-</sup></i> mice and s	sensitized, had significantly less severe
and extent of infiltration with inflammatory cells. These results indicate that microbiome significantly affects sensitivity to asthma and lung inflammation and that microbiome from Pglyrp1-deficient mice reduces allergic inflammatory response in the lungs compared with microbiome from wild-type mice.         15. SUBJECT TERMS         Asthma, Acute Lung Injury, Microbiome, Innate Immunity, Peptidoglycan Recognition Protein 1, Pglyrp1         16. SECURITY CLASSIFICATION OF:       17. LIMITATION OF ABSTRACT         a. REPORT       b. ABSTRACT         c. THIS PAGE       18         Unclassified       19b. TELEPHONE NUMBER (include area code)	asthma and lung infla	mmation than gern	n-free mice colonized	with microbiomes from	m wild-type mi	ce, as measured by lung resistance test
inflammation and that microbiome from <i>Pglyrp1</i> -deficient mice reduces allergic inflammatory response in the lungs compared with microbiome from wild-type mice.          15. SUBJECT TERMS         Asthma, Acute Lung Injury, Microbiome, Innate Immunity, Peptidoglycan Recognition Protein 1, Pglyrp1         16. SECURITY CLASSIFICATION OF:       17. LIMITATION OF ABSTRACT         a. REPORT       b. ABSTRACT       c. THIS PAGE         Unclassified       18	and extent of infiltrat	ion with inflammat	tory cells. These results	s indicate that microbi	ome significant	ly affects sensitivity to asthma and lung
microbiome from wild-type mice.         15. SUBJECT TERMS         Asthma, Acute Lung Injury, Microbiome, Innate Immunity, Peptidoglycan Recognition Protein 1, Pglyrp1         16. SECURITY CLASSIFICATION OF:       17. LIMITATION OF ABSTRACT       18. NUMBER OF PAGES       19a. NAME OF RESPONSIBLE PERSON USAMRMC         a. REPORT       b. ABSTRACT       c. THIS PAGE       18       19b. TELEPHONE NUMBER (include area code)	inflammation and that	t microbiome from	<i>Pglvrn1</i> -deficient mic	e reduces allergic infl	ammatory resp	onse in the lungs compared with
15. SUBJECT TERMS         Asthma, Acute Lung Injury, Microbiome, Innate Immunity, Peptidoglycan Recognition Protein 1, Pglyrp1         16. SECURITY CLASSIFICATION OF:       17. LIMITATION OF ABSTRACT       18. NUMBER OF PAGES       19a. NAME OF RESPONSIBLE PERSON USAMRMC         a. REPORT       b. ABSTRACT       c. THIS PAGE       18       19b. TELEPHONE NUMBER (include area code)	microbiome from wi	d-type mice	57 r			
15. SUBJECT TERMS         Asthma, Acute Lung Injury, Microbiome, Innate Immunity, Peptidoglycan Recognition Protein 1, Pglyrp1         16. SECURITY CLASSIFICATION OF:       17. LIMITATION OF ABSTRACT       18. NUMBER OF PAGES       19a. NAME OF RESPONSIBLE PERSON USAMRMC         a. REPORT       b. ABSTRACT       c. THIS PAGE       18       19b. TELEPHONE NUMBER (include area code)		Jr				
Asthma, Acute Lung Injury, Microbiome, Innate Immunity, Peptidoglycan Recognition Protein 1, Pglyrp1          16. SECURITY CLASSIFICATION OF:       17. LIMITATION OF ABSTRACT       18. NUMBER OF PAGES       19a. NAME OF RESPONSIBLE PERSON USAMRMC         a. REPORT       b. ABSTRACT       c. THIS PAGE       18       19b. TELEPHONE NUMBER (include area code)						
Astnma, Acute Lung Injury, Microbiome, Innate Immunity, Peptidoglycan Recognition Protein 1, Pglyrp1         16. SECURITY CLASSIFICATION OF:       17. LIMITATION OF ABSTRACT       18. NUMBER OF PAGES       19a. NAME OF RESPONSIBLE PERSON USAMRMC         a. REPORT       b. ABSTRACT       c. THIS PAGE       18       19b. TELEPHONE NUMBER (include area code)	15. SUBJECT TERMS	. I. S. Missel	· · · · · · · · · · · · · · · · · · ·	. D 1 1 D		- 4 - in 1 D - 1 - m 1
16. SECURITY CLASSIFICATION OF:     17. LIMITATION OF ABSTRACT     18. NUMBER OF PAGES     19a. NAME OF RESPONSIBLE PERSON USAMRMC       a. REPORT     b. ABSTRACT     c. THIS PAGE     18     19b. TELEPHONE NUMBER (include area code)	Asthma, Acute Lur	ig Injury, Microb	iome, Innate Immuni	ity, Peptidoglycan R	ecognition Pr	otein I, Pglyrpl
16. SECURITY CLASSIFICATION OF:     17. LIMITATION OF ABSTRACT     18. NUMBER OF PAGES     19a. NAME OF RESPONSIBLE PERSON USAMRMC       a. REPORT     b. ABSTRACT     c. THIS PAGE     18     19b. TELEPHONE NUMBER (include area code)				1	1	
a. REPORT b. ABSTRACT c. THIS PAGE USAMRMC Unclassified Usample Code Code Code Code Code Code Code Cod	16. SECURITY CLASS	FICATION OF:		17. LIMITATION	18. NUMBER	19a. NAME OF RESPONSIBLE PERSON
a. REPORT b. ABSTRACT c. THIS PAGE 18 19b. TELEPHONE NUMBER (include area code)				OF ABSTRACT	OF PAGES	USAMRMC
Unclassified <sup>code)</sup>	a. REPORT	b. ABSTRACT	c. THIS PAGE		18	19b. TELEPHONE NUMBER (include area
				Unclassified		coae)
Unclassified Unclassified Unclassified	Unclassified	Unclassified	Unclassified			

# TABLE OF CONTENTS

# Page No.

1.	Introduction	4
2.	Keywords	4
3.	Accomplishments	4
4.	Impact	12
5.	Changes/Problems	13
6.	Products	14
7.	Participants & Other Collaborating Organizations	16
8.	Special Reporting Requirements	18
9.	Appendices	None

# 1. INTRODUCTION:

This project is testing an emerging idea that the abundance and the composition of respiratory and intestinal microbiomes controls sensitivity to asthma and that one of the important host factors that controls the abundance and composition of microbiome is antibacterial innate immunity protein, **Peptidoglycan Recognition Protein 1** (*Pglyrp1*). The role of *Pglyrp1*-controlled respiratory and intestinal tract microfloras in the sensitivity to asthma and lung and airways inflammation is being tested using a mouse model of experimentally induced asthma.

# 2. KEYWORDS:

Asthma, Acute Lung Injury, Microbiome, Innate Immunity, Peptidoglycan Recognition Protein 1, Pglyrp1

**3. ACCOMPLISHMENTS:** The PI is reminded that the recipient organization is required to obtain prior written approval from the awarding agency Grants Officer whenever there are significant changes in the project or its direction.

# What were the major goals of the project?

List the major goals of the project as stated in the approved SOW. If the application listed milestones/target dates for important activities or phases of the project, identify these dates and show actual completion dates or the percentage of completion.

Major Task 1: Obtain IUSM-NW IACUC and DoD ACURO Animal Care and Use Application reviews and approvals	Month 1	100% completed
<i>Milestone(s) Achieved:</i> IUSM-NW IACUC and DoD ACURO Animal Care and Use Application approvals obtained		Completed
<b>Specific Aim 1: Identify</b> <i>Pglyrp1</i> -controlled microflora in respiratory and intestinal tract microbiomes		
Major Task 2: Collect respiratory tract and intestinal microbiome samples from WT and <i>Pglyrp1<sup>-/-</sup></i> mice, isolate bacterial DNA, sequence bacterial 16R rRNA genes, and analyze composition of microbiomes	Months 1–3	75% completed
<i>Milestone(s) Achieved:</i> Identification of bacterial diversity in the respiratory and intestinal tracts of WT and <i>Pglyrp1<sup>-/-</sup></i> mice, and identification of significant differences in these bacteria between <i>Pglyrp1<sup>-/-</sup></i> and WT mice		Subtasks 1–2 completed, Subtasks 3–4 in progress
<b>Specific Aim 2: Determine the role of </b> <i>Pglyrp1</i> <b>-controlled</b> <b>respiratory and intestinal tract microfloras in the changed</b> <b>sensitivity of mice to asthma and lung and airways</b> <b>inflammation</b>		

Major Task 3: Determine the role of the entire respiratory microbiome and intestinal microbiome of WT and <i>Pglyrp1<sup>-/-</sup></i> mice in sensitivity to asthma	Months 4–10	100% completed
<i>Milestone(s) Achieved:</i> Identification of the ability of respiratory and/or intestinal microflora from WT and <i>Pglyrp1</i> <sup>-/-</sup> mice to control sensitivity to asthma		Subtasks 1–4 completed
Major Task 4: Determine the role of microflora that is more abundant in <i>Pglyrp1<sup>-/-</sup></i> than in WT mice in controlling sensitivity to asthma	Months 11–14	In progress
<i>Milestone(s) Achieved:</i> Identification of the ability of bacteria that are more abundant in <i>Pglyrp1</i> <sup>-/-</sup> mice than in WT mice to control sensitivity to asthma		In progress
Major Task 5: Determine the role of microflora that is more abundant in WT than in <i>Pglyrp1<sup>-/-</sup></i> mice in controlling sensitivity to asthma	Months 15–18	In progress
<i>Milestone(s) Achieved:</i> Identification of the ability of bacteria that are more abundant in WT mice than in <i>Pglyrp1</i> <sup>-/-</sup> mice to control sensitivity to asthma		In progress

# What was accomplished under these goals?

For this reporting period describe: 1) major activities; 2) specific objectives; 3) significant results or key outcomes, including major findings, developments, or conclusions (both positive and negative); and/or 4) other achievements. Include a discussion of stated goals not met. Description shall include pertinent data and graphs in sufficient detail to explain any significant results achieved. A succinct description of the methodology used shall be provided. As the project progresses to completion, the emphasis in reporting in this section should shift from reporting activities to reporting accomplishments.

**Results reported previously for period: July 1, 2016 – June 30, 2017:** 

**Major Task 1:** IUSM-NW IACUC and DoD ACURO Animal Care and Use Application approvals obtained.

<u>Specific Aim 1</u>: Identify *Pglyrp1*-controlled microflora in respiratory and intestinal tract microbiomes

Major Task 2: Collect respiratory tract and intestinal microbiome samples from WT and *Pglyrp1*<sup>-/-</sup> mice, isolate bacterial DNA, sequence bacterial 16R rRNA genes, and analyze composition of microbiomes

Subtask 1: Collect respiratory tract and intestinal microbiome samples from WT and Pglyrp1<sup>-/-</sup> mice.

The samples were collected and persevered.

Subtasks 2–4: Isolate bacterial DNA from respiratory tract and intestinal microbiome samples from WT and  $Pglyrp1^{-/-}$  mice; Perform pyrosequencing of bacterial 16R rRNA genes in DNA samples obtained in subtask 2 and assign sequences to taxonomic units; Compare diversity of operational taxonomic units (OTUs), species, genera, families, orders, classes, and phyla in respiratory and intestinal microbiomes and determine significant differences between WT and  $Pglyrp1^{-/-}$  mice; identify species significantly increased in WT and  $Pglyrp1^{-/-}$  mice.

# New results for the current annual reporting period: July 1, 2017 – June 30, 2018:

These Subtasks are in progress, as we are performing this Subtask after completing Major Task 3. The reason for performing Subtasks 2–4 after completing Major Task 3 is that we wanted to make sure that the microbiomes we are sequencing and analyzing have the capacity to modulate the sensitivity to asthma. As described below under Major Task 3, mice depleted of microbiome with antibiotics and colonized with microflora from WT or  $Pglyrp1^{-/-}$  mice did not show significant differences in severity of asthma (Experiment 1). However, germ-free mice, both outbred (Swiss-Webster) and inbred BALB/c, colonized with microflora from WT or  $Pglyrp1^{-/-}$  mice showed significant differences in severity of asthma (Experiments 2 and 3). Because BALB/c mice showed more characteristic features of asthma, microbiomes from these mice are being currently analyzed.

# **Results reported previously for period: July 1, 2016 – June 30, 2017:**

<u>Specific Aim 2</u>: Determine the role of *Pglyrp1*-controlled respiratory and intestinal tract microfloras in the changed sensitivity of mice to asthma and lung and airways inflammation Major Task 3: Determine the role of the entire respiratory microbiome and intestinal microbiome of WT and *Pglyrp1*<sup>-/-</sup> mice in sensitivity to asthma

Subtask 1: Collect and preserve respiratory and intestinal microflora from WT and Pglyrp1<sup>-/-</sup> mice.

We collected the microflora samples, preserved them, and used them in Subtask 2.

Subtask 2: Colonize germ-free or antibiotic-treated mice with respiratory microflora, intestinal microflora, or both microfloras from WT or  $Pglyrp1^{-/-}$  mice.

Subtask 3: Sensitize mice from subtask 2 with HDM allergen and induce asthmatic inflammatory response to HDM.

Subtask 4: Measure the severity of asthma and lung and airways inflammation in mice from subtask 3.

In **Experiment 1**, we depleted microbiomes in conventional WT BALB/c male and female mice using 3-week long antibiotic treatment, we mated these mice, and then we colonized pregnant females with respiratory and intestinal microfloras from WT or from  $Pglyrp1^{-/-}$  mice. We continued re-colonizing nursing mothers until weaning, and then we continued re-colonizing pups after weaning throughout the entire experiment. At 6 weeks of age we began intranasal sensitization of the pups with house dust mite

(HDM) allergen, which we continued for 5 weeks to induce chronic asthma-like lung inflammation. We then measured the severity of asthma and lung and airways inflammation using lung function and histopathologic and immunologic tests (Fig. 1).



Fig. 1. Experimental timeline for depletion of microflora in BALB/c mice with oral antibiotics and colonization of pregnant mice and pups with respiratory and intestinal microfloras from WT or from  $Pglyrp1^{-/-}$  mice, sensitization of pups with HDM, and asthma assays (Experiment 1).

Experiment 1 results: Both groups of mice (colonized with microfloras from WT or from  $Pglyrp1^{-/-}$  mice) had similar severity of asthma and lung inflammation, as measured by lung resistance test (Fig. 2) and extent of infiltration with inflammatory cells (Fig. 3). These results could be interpreted in two ways: (i) the effect of microbiome from  $Pglyrp1^{-/-}$  mice could not be demonstrated because antibiotics did not sufficiently deplete the microflora in the parents and the original microflora came back and became dominant over the colonized microflora after antibiotic treatment was stopped; or (ii) microbiome from  $Pglyrp1^{-/-}$  mice did get established, but had no effect on the severity of asthma and lung inflammation. To distinguish between these two possibilities, Experiment 2 was then performed.



Fig. 2. Lung airway resistance in response to methacholine in microflora-depleted BALB/c mice colonized with respiratory and intestinal microfloras from WT or from  $Pglyrp1^{-/-}$  mice and sensitized with HDM, as shown in Fig. 1. The results are means  $\pm$  SEM of 11 mice per group. The differences between WT and  $Pglyrp1^{-/-}$  groups were not statistically significant (Experiment 1).



Fig. 3. Inflammatory cells in bronchoalveolar lavage (BAL) fluid and lungs in microflora-depleted BALB/c mice colonized with respiratory and intestinal microfloras from WT or from  $Pglyrp1^{-/-}$  mice and sensitized with HDM, as shown in Fig. 1. The results are means ± SEM of 11 mice per group. The differences between WT and  $Pglyrp1^{-/-}$  groups were not statistically significant (Experiment 1).

**Experiment 2** was performed the same way as Experiment 1, but Germ-free WT Swiss-Webster mice were used instead of antibiotic-treated conventional mice, to start with mice completely devoid of microbiome and to eliminate the possibility of incomplete depletion and re-emergence of the original microbiome (Fig. 4).

<b>Pregnant</b> germ-free mice	<b>Pup</b> Mot	<b>os born</b> hers and	d pups		Pup	os weai	ned				<b>As</b> lun cel pat	<b>say</b> g function l types thology
-1 week	$\downarrow$	4	weeks		$\downarrow$			7 we	eks			$\downarrow$
<b>↑</b>	^	Ŷ	↑	↑	↑	↑	Ŷ	↑	↑	↑	1	
Gavage	Mot	thers:			Pup	s:	Gavag	ge with s	stools			
stools		Gava	ge with	stools	Oro-nasal flora							
Oro-nasal flora Co-house	Oro-nasal flora						111	↑↑ ↑↑↑ Sensitiz	↑↑ ↑↑↑ e with ir	↑↑ ↑↑↑ itranasa	↑↑ ↑↑↑ I HDM	$\uparrow\uparrow$

Fig. 4. Experimental timeline for colonization of germ-free pregnant WT Swiss-Webster mice and pups with respiratory and intestinal microfloras from WT or from  $Pglyrp1^{-/-}$  mice, sensitization of pups with HDM, and asthma assays (Experiment 2).

Experiment 2 results: Germ-free WT Swiss-Webster mice colonized with microbiomes from  $Pglyrp1^{-/-}$  mice had significantly less severe asthma and lung inflammation than Germ-free mice colonized with microbiomes from WT mice, as measured by lung resistance test (Fig. 5) and extent of infiltration with inflammatory cells (Fig. 6). These data indicate that microbiome significantly affects sensitivity to asthma and lung inflammation and that microbiome from  $Pglyrp1^{-/-}$  mice reduces allergic inflammatory response in the lungs compared with microbiome from WT mice.



Fig. 5. Lung airway resistance in response to methacholine in germ-free WT Swiss-Webster mice colonized with respiratory and intestinal microfloras from WT or from  $Pglyrp1^{-/-}$  mice and sensitized with HDM, as shown in Fig. 4. The results are means  $\pm$  SEM of 12 mice per group; \* P < 0.05 for WT versus  $Pglyrp1^{-/-}$  groups (*t*-test) (Experiment 2).



Fig. 6. Inflammatory cells in BAL fluid and lungs in germ-free WT Swiss-Webster mice colonized with respiratory and intestinal microfloras from WT or from  $Pglyrp1^{-/-}$  mice and sensitized with HDM, as shown in Fig. 4. The results are means  $\pm$  SEM of 12 mice per group; \* P < 0.05, \*\* P < 0.001, for WT versus  $Pglyrp1^{-/-}$  groups (*t*-test) (Experiment 2).

# New results for the current annual reporting period: July 1, 2017 – June 30, 2018:

Lung sections were prepared from unsensitized control mice and HDM-sensitized mice from Experiment 2, to further characterize the extent and the type of inflammatory response in these mice affected by colonization with these two types of microbiomes. WT Swiss-Webster mice colonized with respiratory and intestinal microflora from *Pglyrp1*<sup>-/-</sup> mice had less prominent cellular infiltrates in the lungs than mice colonized with microflora from WT mice. However, both groups of sensitized mice had very few eosinophils infiltrating the lungs. These mice also did not have prominent goblet cells hyperplasia and metaplasia. Eosinophil infiltration and goblet cells hyperplasia and metaplasia are very characteristic of allergic asthma in humans.

We concluded, that although the colonized Swiss-Webster mice become sensitized with HDM and showed inflammatory response in the lungs, these mice did not develop typical allergic inflammation seen in human asthma and in experimental asthma in BALB/c mice, characterized by high eosinophilic response and goblet cells hyperplasia and metaplasia. This difference was probably due to genetic differences between Swiss-Webster and BALB/c mice. BALB/c mice are a preferred model of human asthma, because similar to humans with asthma, BALB/c mice develop an allergic eosinophilic

response to respiratory HDM sensitization. We used Swiss-Webster germ-free mice in Experiment 2, because germ-free BALB/c mice were not available when we started this project. However, in the summer of 2017 germ-free BALB/c mice became available for the first time. Because BALB/c mice better mimic human asthma, in this second year of this project we decided to preform Experiment 3 using Germ-free BALB/c mice.

**Experiment 3** was performed the same way as Experiment 2, but Germ-free WT BALB/c mice were used instated of Swiss-Webster mice (Fig. 7).

Pregnant germ-free mice	<b>Pup</b> Mot	<b>s born</b> hers and	l pups		Pup	os wea	ned	_			<b>As</b> lun cel pat	<b>say</b> Ig function I types thology
-1 week	_↓	4	weeks		↓	↓ 7 weeks						<u> </u>
<b>↑</b>	^	$\uparrow$	↑	↑	↑	↑	↑	1	$\uparrow$	↑	1	
Gavage	<b>Mothers:</b> Gavage with stools				Pups: Gavage with stools							
stools					Oro-nasal flora							
Oro-nasal flora Co-house		Oro	-nasal f	lora			<b>111</b>	↑↑ ↑↑↑ Sensitiz	↑↑ ↑↑↑ e with ir	↑↑ ↑↑↑ tranasa	↑↑ ↑↑↑↑ I HDM	$\uparrow\uparrow$

Fig. 7. Experimental timeline for colonization of germ-free pregnant WT BALB/c mice and pups with respiratory and intestinal microfloras from WT or from  $Pglyrp1^{-/-}$  mice, sensitization of pups with HDM, and asthma assays (Experiment 3).

Experiment 3 results: Germ-free WT BALB/c mice colonized with microbiomes from  $Pglyrp1^{-/-}$  mice had significantly less severe asthma and lung inflammation than Germ-free mice colonized with microbiomes from WT mice, as measured by lung resistance test (Fig. 8) and extent of infiltration with inflammatory cells (Fig. 9). These data indicate that microbiome significantly affects sensitivity to asthma and lung inflammation and that microbiome from  $Pglyrp1^{-/-}$  mice reduces allergic inflammatory response in the lungs compared with microbiome from WT mice.



Fig. 8. Lung airway resistance in response to methacholine in germ-free WT BALB/c mice colonized with respiratory and intestinal microfloras from WT or from  $Pglyrp1^{-/-}$  mice and sensitized with HDM, as shown in Fig. 7. The results are means  $\pm$  SEM of 12–14 mice per group; \* P < 0.05 for WT versus  $Pglyrp1^{-/-}$  groups (*t*-test) (Experiment 3).



Fig. 9. Inflammatory cells in BAL fluid and lungs in germ-free WT BALB/c mice colonized with respiratory and intestinal microfloras from WT or from  $Pglyrp1^{-/-}$  mice and sensitized with HDM, as shown in Fig. 7. The results are means  $\pm$  SEM of 12–14 mice per group; \* P < 0.05, \*\* P < 0.001, for WT versus  $Pglyrp1^{-/-}$  groups (*t*-test) (Experiment 3).

Lung sections were prepared from unsensitized control mice and HDM-sensitized mice from Experiment 3, to further characterize the extent and the type of inflammatory response in these mice affected by colonization with these two types of microbiomes. WT BALB/c mice colonized with respiratory and intestinal microflora from  $Pglyrp1^{-/-}$  mice had less prominent cellular infiltrates in the lungs than mice colonized with microflora from WT mice. The infiltrates primarily contained lymphocytes and macrophages, with moderate numbers of eosinophils and neutrophils. The mice colonized with WT microflora also had prominent hyperplasia and metaplasia of mucus-filled goblet cells, which were less prominent in mice colonized with microbiome from  $Pglyrp1^{-/-}$  mice. Both infiltrates and goblet cells are very characteristic of allergic asthma in humans.

# What opportunities for training and professional development has the project provided?

If the project was not intended to provide training and professional development opportunities or there is nothing significant to report during this reporting period, state "Nothing to Report."

Describe opportunities for training and professional development provided to anyone who worked on the project or anyone who was involved in the activities supported by the project. "Training" activities are those in which individuals with advanced professional skills and experience assist others in attaining greater proficiency. Training activities may include, for example, courses or one-on-one work with a mentor. "Professional development" activities result in increased knowledge or skill in one's area of expertise and may include workshops, conferences, seminars, study groups, and individual study. Include participation in conferences, workshops, and seminars not listed under major activities.

#### Nothing to Report

#### How were the results disseminated to communities of interest?

If there is nothing significant to report during this reporting period, state "Nothing to Report."

Describe how the results were disseminated to communities of interest. Include any outreach activities that were undertaken to reach members of communities who are not usually aware of

these project activities, for the purpose of enhancing public understanding and increasing interest in learning and careers in science, technology, and the humanities.

Nothing to Report

# What do you plan to do during the next reporting period to accomplish the goals?

If this is the final report, state "Nothing to Report." Describe briefly what you plan to do during the next reporting period to accomplish the goals and objectives.

# Plans for the remaining period of no-cost extension (1 July, 2018 - 31 December, 2018)

During the **remaining period of no-cost extension**, we plan to complete the remaining experiments in Major Task 3, Major Task 4, and Major Task 5, using the samples from Experiment 3, as outlined above under the "Goals of the project" and described in detail in our original SOW. The timeline for our experiments was delayed because of changes in the personnel and the necessity to perform an additional experiment (Experiment 3) using germ-free BALB/c mice that were not available during the first year of the project.

4. IMPACT: Describe distinctive contributions, major accomplishments, innovations, successes, or any change in practice or behavior that has come about as a result of the project relative to:

What was the impact on the development of the principal discipline(s) of the project? If there is nothing significant to report during this reporting period, state "Nothing to Report."

Describe how findings, results, techniques that were developed or extended, or other products from the project made an impact or are likely to make an impact on the base of knowledge, theory, and research in the principal disciplinary field(s) of the project. Summarize using language that an intelligent lay audience can understand (Scientific American style).

The **short-term impact** of our project so far is that our data support the hypothesis that *Pglyrp1* gene controls the composition of respiratory and/or intestinal microflora, and that this microflora influences the sensitivity to asthma and lung inflammation. This conclusion will be further verified in the second year of this project, along with an attempt to identify the groups of bacterial species responsible for this effect.

The **long-term impact** of this project (once completed) will be future application of these results for the development of new prevention and treatment methods for asthma and other inflammatory diseases. These methods will involve modulating expression or activity of innate immunity molecules that control microbiome, or re-balancing respiratory and/or intestinal microflora to maximize its beneficial effect, by increasing asthma-protective microflora and eradicating asthma-promoting microflora.

# What was the impact on other disciplines?

If there is nothing significant to report during this reporting period, state "Nothing to Report."

Describe how the findings, results, or techniques that were developed or improved, or other products from the project made an impact or are likely to make an impact on other disciplines.

Nothing to Report

#### What was the impact on technology transfer?

If there is nothing significant to report during this reporting period, state "Nothing to Report."

Describe ways in which the project made an impact, or is likely to make an impact, on commercial technology or public use, including:

- *transfer of results to entities in government or industry;*
- *instances where the research has led to the initiation of a start-up company; or*
- *adoption of new practices.*

Nothing to Report

#### What was the impact on society beyond science and technology?

If there is nothing significant to report during this reporting period, state "Nothing to Report."

Describe how results from the project made an impact, or are likely to make an impact, beyond the bounds of science, engineering, and the academic world on areas such as:

- *improving public knowledge, attitudes, skills, and abilities;*
- *changing behavior, practices, decision making, policies (including regulatory policies), or social actions; or*
- *improving social, economic, civic, or environmental conditions.*

Nothing to Report

**5. CHANGES/PROBLEMS:** The Project Director/Principal Investigator (PD/PI) is reminded that the recipient organization is required to obtain prior written approval from the awarding agency Grants Officer whenever there are significant changes in the project or its direction. If not previously reported in writing, provide the following additional information or state, "Nothing to Report," if applicable:

#### Changes in approach and reasons for change

Describe any changes in approach during the reporting period and reasons for these changes. Remember that significant changes in objectives and scope require prior approval of the agency.

Some of the subtasks that were originally planned for year 1 of the project will be now completed in year 2 during the no-cost extension. This delay was caused by the need to search for and to hire new personnel for the project, and also the need to perform the additional Experiment 3 in Major Task 3, as described in Section 3 Accomplishments.

#### Actual or anticipated problems or delays and actions or plans to resolve them

Describe problems or delays encountered during the reporting period and actions or plans to resolve them.

A delay in performing some of the subtasks was caused by the need to find and hire new appropriately qualified research personnel to perform the experiments and the need to obtain their visas, and also by the necessity to perform an additional experiment (Experiment 3). We are planning to complete the remaining tasks during the no-cost extension.

#### Changes that had a significant impact on expenditures

Describe changes during the reporting period that may have had a significant impact on expenditures, for example, delays in hiring staff or favorable developments that enable meeting objectives at less cost than anticipated.

Nothing to Report

# Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents

Describe significant deviations, unexpected outcomes, or changes in approved protocols for the use or care of human subjects, vertebrate animals, biohazards, and/or select agents during the reporting period. If required, were these changes approved by the applicable institution committee (or equivalent) and reported to the agency? Also specify the applicable Institutional Review Board/Institutional Animal Care and Use Committee approval dates.

#### Significant changes in use or care of human subjects

No significant changes.

#### Significant changes in use or care of vertebrate animals.

No significant changes.

#### Significant changes in use of biohazards and/or select agents

No significant changes.

**6. PRODUCTS:** List any products resulting from the project during the reporting period. If there is nothing to report under a particular item, state "Nothing to Report."

**Publications, conference papers, and presentations** Report only the major publication(s) resulting from the work under this award.

**Journal publications.** List peer-reviewed articles or papers appearing in scientific, technical, or professional journals. Identify for each publication: Author(s); title; journal; volume: year; page numbers; status of publication (published; accepted, awaiting publication; submitted, under review; other); acknowledgement of federal support (yes/no).

Nothing to Report.

**Books or other non-periodical, one-time publications.** Report any book, monograph, dissertation, abstract, or the like published as or in a separate publication, rather than a periodical or series. Include any significant publication in the proceedings of a one-time conference or in the report of a one-time study, commission, or the like. Identify for each one-time publication: Author(s); title; editor; title of collection, if applicable; bibliographic information; year; type of publication (e.g., book, thesis or dissertation); status of publication (published; accepted, awaiting publication; submitted, under review; other); acknowledgement of federal support (yes/no).

Nothing to Report.

**Other publications, conference papers, and presentations**. *Identify any other publications, conference papers and/or presentations not reported above. Specify the status of the publication as noted above. List presentations made during the last year (international, national, local societies, military meetings, etc.). Use an asterisk (\*) if presentation produced a manuscript.* 

Presentation by Roman Dziarski, titled "PGRPs – antibacterial proteins that regulate microbiome and inflammation", at Yale University, New Haven, CT, April 13, 2018.

Presentation by Roman Dziarski, titled "Peptidoglycan recognition proteins kill bacteria by inducing oxidative stress through a block in the respiratory chain", at Gordon Research Conference: The Bacterial Cell Envelope: From Mechanism of Assembly to Role in the Physiology of Single Cells and Communities, Mount Snow, VT, June 27, 2018.

# • Website(s) or other Internet site(s)

List the URL for any Internet site(s) that disseminates the results of the research activities. A short description of each site should be provided. It is not necessary to include the publications already specified above in this section.

Nothing to Report.

# • Technologies or techniques

Identify technologies or techniques that resulted from the research activities. In addition to a description of the technologies or techniques, describe how they will be shared.

Nothing to Report.

#### • Inventions, patent applications, and/or licenses

Identify inventions, patent applications with date, and/or licenses that have resulted from the research. State whether an application is provisional or non-provisional and indicate the application number. Submission of this information as part of an interim research performance progress report is not a substitute for any other invention reporting required under the terms and conditions of an award.

Nothing to Report.

# Other Products

Identify any other reportable outcomes that were developed under this project. Reportable outcomes are defined as a research result that is or relates to a product, scientific advance, or research tool that makes a meaningful contribution toward the understanding, prevention, diagnosis, prognosis, treatment, and/or rehabilitation of a disease, injury or condition, or to improve the quality of life. Examples include:

- data or databases;
- biospecimen collections;
- audio or video products;
- software;
- models;
- educational aids or curricula;
- *instruments or equipment;*
- research material (e.g., Germplasm; cell lines, DNA probes, animal models);
- *clinical interventions;*
- new business creation; and
- *other*.

Nothing to Report.

# 7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

# What individuals have worked on the project?

Provide the following information for: (1) PDs/PIs; and (2) each person who has worked at least one person month per year on the project during the reporting period, regardless of the source of compensation (a person month equals approximately 160 hours of effort). If information is unchanged from a previous submission, provide the name only and indicate "no change." Example:

<u>Example.</u>	
Name:	Mary Smith
Project Role:	Graduate Student
Researcher Identifier (e.g. ORCID ID):	1234567
Nearest person month worked:	5
Contribution to Project:	Ms. Smith has performed work in the area of
	<i>combined error-control and constrained coding.</i>

The Ford Foundation (Complete only if the funding support is provided from other than this award).

Name: Project Role: Nearest person month worked: Contribution to Project:	Roman Dziarski Principal Investigator 1 Dr. Dziarski planned, designed, and performed the experiments, and analyzed the results.
Name:	Sunil Banskar
Project Role:	Postdoctoral Fellow
Nearest person month worked:	9
Contribution to Project:	Dr. Banskar performed the experiments on Major Tasks 2 and 3.

# Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?

If there is nothing significant to report during this reporting period, state "Nothing to Report."

If the active support has changed for the PD/PI(s) or senior/key personnel, then describe what the change has been. Changes may occur, for example, if a previously active grant has closed and/or if a previously pending grant is now active. Annotate this information so it is clear what has changed from the previous submission. Submission of other support information is not necessary for pending changes or for changes in the level of effort for active support reported previously. The awarding agency may require prior written approval if a change in active other support significantly impacts the effort on the project that is the subject of the project report.

Current Active Support:

Source and Project Number: NIH 1R01AI120962-01
Principal Investigator: Dziarski, Roman
Title of Project: Antibacterial activity of peptidoglycan recognition proteins
Percent Effort: 20%
Dates of Project: 07/06/2016 - 06/30/2020
Total Direct Costs: \$1,000,000
Total Costs: \$1,571,250
Goals: The major goal of this project is to determine the mechanism of bactericidal activity of
peptidoglycan recognition proteins (PGRP).
Specific Aims:
1. We will determine that each of the 13 proposed events actually happens during PGRP
killing of bacteria.
2. We will determine which of these 13 proposed events participate in PGRP-induced killing
and which in bacterial defense against killing, or which are a consequence of killing.
3. We will determine the sequence of these 13 proposed events in PGRP-induced killing and
which events are sequential and which parallel.
Overlap: There is no overlap with this DoD project.

#### What other organizations were involved as partners?

If there is nothing significant to report during this reporting period, state "Nothing to Report."

Describe partner organizations – academic institutions, other nonprofits, industrial or commercial firms, state or local governments, schools or school systems, or other organizations (foreign or domestic) – that were involved with the project. Partner organizations may have provided financial or in-kind support, supplied facilities or equipment, collaborated in the research, exchanged personnel, or otherwise contributed. Provide the following information for each partnership: <u>Organization Name:</u> Location of Organization: (if foreign location list country)

Partner's contribution to the project (identify one or more)

- *Financial support;*
- *In-kind support (e.g., partner makes software, computers, equipment, etc., available to project staff);*
- Facilities (e.g., project staff use the partner's facilities for project activities);
- Collaboration (e.g., partner's staff work with project staff on the project);
- Personnel exchanges (e.g., project staff and/or partner's staff use each other's facilities, work at each other's site); and
- Other.

Nothing to Report.

# 8. SPECIAL REPORTING REQUIREMENTS

#### COLLABORATIVE AWARDS: N/A

QUAD CHARTS: N/A

# 9. APPENDICES: No Appendices.